Psychedelic and ketamine research trials in the United States
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
544 registered studies are counted in the United States. By compound: 191 psilocybin, 68 MDMA, 12 LSD, 10 DMT, 4 5-MeO-DMT, 271 ketamine and 4 ibogaine. By registry status: 130 recruiting, 35 not yet recruiting, 9 enrolling by invitation, 43 active, not recruiting, 225 completed, 37 terminated, 4 suspended, 38 withdrawn and 23 status not reported. By phase: 41 early phase 1, 156 phase 1, 203 phase 2, 44 phase 3, 35 phase 4, 34 not applicable and 31 not reported. Reported start years run from 2002 (earliest) to 2027 (latest). Studies are linked to 221 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
165 of the 544 counted studies are listed in the registry as recruiting (130) or not yet recruiting (35), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Psilocybin for Methamphetamine Use Disorder | NCT07774702 | Not yet recruiting | Phase 2 | 2027-02-01 | University of Alabama at Birmingham, Birmingham |
| Group PACBT for Depression | NCT07566104 | Not yet recruiting | Phase 2 | 2027-01-01 | University of California, Los Angeles, Los Angeles |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life | NCT07719088 | Not yet recruiting | Phase 1 | 2026-12-01 | Vail Health Behavioral Health, Edwards |
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response | NCT07768618 | Not yet recruiting | Phase 2 | 2026-12-01 | Emory University, Atlanta |
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | NCT07833761 | Not yet recruiting | Phase 1 | 2026-12-01 | University of Minnesota, Minneapolis |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV | NCT07756736 | Not yet recruiting | Phase 2 | 2026-11-01 | University of California, San Francisco, San Francisco |
| Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation | NCT07818564 | Recruiting | Phase 1 | 2026-11-01 | Brown University, Providence |
| MDMA-AT for PTSD in Young Adults With Childhood Trauma | NCT07765693 | Not yet recruiting | Phase 2 | 2026-10-31 | Mclean Hospital, Belmont |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | NCT07721467 | Recruiting | Phase 2 | 2026-10-01 | National Institutes of Health Clinical Center (CC), Baltimore |
| Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department | NCT07868913 | Recruiting | Phase 2 | 2026-09-30 | Carl R Darnall Army Medical Center, Fort Hood |
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | NCT07570654 | Recruiting | Phase 2 | 2026-09-01 | COMPASS Pathways, Gilbert |
| Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) | NCT07693257 | Not yet recruiting | Phase 1 | 2026-09-01 | University of California, San Diego, La Jolla |
| The Effects of Psilocybin on Social Connectedness | NCT07693153 | Not yet recruiting | Phase 1 | 2026-08-31 | Yale University, New Haven |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07745569 | Not yet recruiting | Phase 2 | 2026-08-31 | University of New Mexico, Albuquerque |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder | NCT07499583 | Not yet recruiting | Phase 1 | 2026-08-01 | Indiana University, Indianapolis |
| Psilocybin After Trauma Surgery for Pain | NCT07406828 | Not yet recruiting | Phase 1 | 2026-07-01 | University of Pittsburgh, Pittsburgh |
| Anesthesia-Masked Psilocybin Therapy for Major Depression | NCT07479550 | Not yet recruiting | Phase 2 | 2026-07-01 | Stanford University, Stanford |
| Shortened LSD Intervention for Major Depressive Disorder | NCT07503002 | Not yet recruiting | Phase 1 | 2026-07-01 | Johns Hopkins University, Baltimore |
| Psilocybin as a Novel Therapy for Residual Anhedonia | NCT07607938 | Recruiting | Phase 1 | 2026-07-01 | NYU Langone Health, New York |
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment | NCT07610135 | Recruiting | Phase 1 | 2026-07-01 | Johns Hopkins University, Baltimore |
| Biomarker-Guided Antidepressant Selection | NCT07680140 | Recruiting | Phase 4 | 2026-07-01 | Weill Medical College of Cornell University, New York |
| Biomarker Discovery for Suicide Precision Circuit Therapeutics | NCT07723066 | Not yet recruiting | Not reported | 2026-07-01 | Massachusetts General Hospital, Palo Alto |
| Psilocybin Administration With 5-HT1a Blockade | NCT07565493 | Recruiting | Early Phase 1 | 2026-06-15 | Johns Hopkins University, Baltimore |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | NCT07226232 | Recruiting | Phase 3 | 2026-06-01 | VA Office of Research and Development, Birmingham |
| Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain | NCT07306364 | Not yet recruiting | Phase 2 | 2026-06-01 | Yale University, New Haven |
| Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression | NCT07565909 | Not yet recruiting | Phase 2 | 2026-06-01 | University of Washington, Seattle |
| Psilocybin-Assisted Therapy as a Treatment for Depression | NCT07582120 | Not yet recruiting | Phase 2 | 2026-06-01 | Washington University School of Medicine, St Louis |
| Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients | NCT07639359 | Recruiting | Phase 2 | 2026-05-14 | Hospital Italiano de Buenos Aires, Jacksonville |
| NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy | NCT07227909 | Not yet recruiting | Phase 2 | 2026-05-04 | M.D. Anderson Cancer Center, Houston |
| Morphine or Ketamine for Analgesia | NCT06835504 | Not yet recruiting | Phase 3 | 2026-05-01 | Columbia University, Los Angeles |
| Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder | NCT07296094 | Not yet recruiting | Phase 2 | 2026-05-01 | Brigham and Women's Hospital, Boston |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | NCT07506395 | Recruiting | Phase 1 | 2026-05-01 | University of New Mexico, Albuquerque |
| MDMA Assisted Therapy for BN | NCT07542145 | Recruiting | Phase 1 | 2026-05-01 | Icahn School of Medicine at Mount Sinai, New York |
| MDMA Therapy in Veterans With PTSD | NCT07569159 | Recruiting | Phase 2 | 2026-05-01 | Sunstone Medical, Rockville |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease | NCT07610369 | Recruiting | Phase 2 | 2026-05-01 | Yale University, New Haven |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | NCT07118839 | Recruiting | Phase 2 | 2026-04-15 | VA Office of Research and Development, West Haven |
| MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers | NCT05455996 | Not yet recruiting | Phase 2 | 2026-04-01 | Nautilus Sanctuary, Boulder |
| MDMA-assisted Therapy for Fibromyalgia | NCT06066853 | Recruiting | Early Phase 1 | 2026-04-01 | Spaulding Rehabilitation Hospital, Charlestown |
| Psilocybin Microdosing on Cognition, Mood and Quality of Life | NCT07449351 | Not yet recruiting | Early Phase 1 | 2026-04-01 | Yale University, Hartford |
| Safety and Tolerability Trial of Psilocybin in Healthy Older Adults | NCT07516405 | Recruiting | Phase 1 | 2026-04-01 | University of Colorado, Denver, San Francisco |
| KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury | NCT07563296 | Recruiting | Phase 2 | 2026-04-01 | University of Utah, Salt Lake City |
| Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression | NCT07563868 | Recruiting | Not applicable | 2026-04-01 | Massachusetts General Hospital, Boston |
| MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | NCT03606538 | Not yet recruiting | Phase 1 | 2026-03-29 | Lykos Therapeutics, Knoxville |
| ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1 | NCT07528014 | Recruiting | Not reported | 2026-03-25 | Salma Health, Inc., La Jolla |
| Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids | NCT06827054 | Not yet recruiting | Phase 2 | 2026-03-15 | Roswell Park Cancer Institute, Buffalo |
| Psilocybin for Prolonged Grief Disorder | NCT06724289 | Recruiting | Early Phase 1 | 2026-03-01 | University of Virginia, Charlottesville |
| Psilocybin-Assisted Randomized Therapy | NCT07332143 | Recruiting | Phase 2 | 2026-03-01 | Emory University, Atlanta |
| A Study of Psychedelics in Healthy Older Adults With Low Well-being | NCT07386730 | Recruiting | Phase 1 | 2026-03-01 | University of California, San Francisco, San Francisco |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | NCT07053917 | Recruiting | Phase 1 | 2026-02-09 | Johns Hopkins University, Baltimore |
| Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | NCT06788249 | Recruiting | Early Phase 1 | 2026-02-01 | University of Pennsylvania, Philadelphia |
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | NCT07139106 | Not yet recruiting | Phase 4 | 2026-02-01 | New York State Psychiatric Institute, New York |
| Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study | NCT07360301 | Not yet recruiting | Phase 1 | 2026-02-01 | University of Wisconsin, Madison, Madison |
| Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement | NCT07369089 | Not yet recruiting | Phase 2 | 2026-02-01 | University of California, San Diego, La Jolla |
| Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter | NCT07296328 | Not yet recruiting | Phase 2 | 2026-01-15 | NYU Langone Health, New York |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | NCT07227454 | Recruiting | Phase 3 | 2026-01-08 | Janssen Research & Development, LLC, Atlanta |
| RCT of Psilocybin-assisted CBT for Depression | NCT07281352 | Recruiting | Phase 1 | 2026-01-05 | University of California, Los Angeles, Los Angeles |
| Ketamine for Opioid Use Disorder | NCT06943859 | Recruiting | Phase 2 | 2026-01-01 | University of Maryland, Baltimore, Baltimore |
| Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study | NCT06988319 | Recruiting | Phase 1 | 2026-01-01 | Oregon Health and Science University, Portland |
| Psilocybin for Treatment of OCD-2 | NCT06992999 | Not yet recruiting | Phase 1 | 2026-01-01 | University of Arizona, Tucson |
| MDMA-Assisted Therapy for Mental Healthcare Providers | NCT07102576 | Recruiting | Phase 1 | 2026-01-01 | Icahn School of Medicine at Mount Sinai, New York |
| Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer | NCT07216404 | Recruiting | Phase 2 | 2026-01-01 | Ohio State University Comprehensive Cancer Center, Columbus |
| Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression | NCT07247006 | Not yet recruiting | Phase 2 | 2026-01-01 | University of Rochester, Rochester |
| Psilocybin to Treat Depression in Spinal Cord Injury | NCT07251491 | Recruiting | Phase 1 | 2026-01-01 | James J. Peters Veterans Affairs Medical Center, The Bronx |
| MDMA-Assisted Massed Exposure Therapy for PTSD | NCT07288151 | Recruiting | Phase 2 | 2026-01-01 | Emory University, Atlanta |
| Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. | NCT07347405 | Recruiting | Phase 1 | 2026-01-01 | University of Arizona, Phoenix |
| Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults | NCT07369024 | Recruiting | Phase 2 | 2026-01-01 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance |
| Psilocybin on Brain Mechanisms of Motivation in OUD | NCT06810310 | Recruiting | Phase 2 | 2025-12-22 | University of Pennsylvania, Philadelphia |
| Ketamine Biomarker Validation | NCT07307768 | Not yet recruiting | Phase 1 | 2025-12-20 | Soterix Medical, New York |
| Psilocybin for Opioid Use Disorder (OUD) | NCT06796062 | Recruiting | Phase 2 | 2025-12-17 | NYU Langone Health, Albuquerque |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | NCT06793397 | Recruiting | Phase 3 | 2025-12-10 | Cybin IRL Limited, Birmingham |
| Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression | NCT06419439 | Recruiting | Phase 2 | 2025-12-03 | VA Office of Research and Development, Ann Arbor |
| A Phase 2A Trial of DT402 for Autism Spectrum Disorder | NCT07303907 | Recruiting | Phase 2 | 2025-12-03 | Definium Therapeutics US, Inc., New York |
| Imaging Depression in Parkinson's Disease | NCT06402955 | Recruiting | Phase 2 | 2025-12-01 | Yale University, New Haven |
| Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD | NCT06902974 | Recruiting | Phase 2 | 2025-12-01 | Sunstone Medical, Rockville |
| Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults | NCT06367738 | Recruiting | Phase 1 | 2025-11-01 | University of California, Berkeley, Berkeley |
| A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety | NCT06820723 | Recruiting | Phase 2 | 2025-11-01 | Ohio State University, Columbus |
| Wellcome Leap Psilocybin for OUD | NCT06786325 | Recruiting | Phase 2 | 2025-10-07 | University of Pennsylvania, Philadelphia |
| Psilocybin as a Treatment for Chronic Pain in Smokers | NCT07118332 | Recruiting | Early Phase 1 | 2025-10-01 | Yale University, West Haven |
| Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | NCT06989957 | Recruiting | Phase 1 | 2025-09-17 | Johns Hopkins University, Baltimore |
| MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | NCT05783817 | Recruiting | Phase 2 | 2025-09-10 | Stanford University, Palo Alto |
| Mapping Ibogaine Neural Dynamics in Opioid Use Disorder | NCT07226570 | Recruiting | Not reported | 2025-09-08 | University of California, Irvine, Irvine |
| MDMA in Borderline Personality Disorder | NCT06683014 | Recruiting | Phase 2 | 2025-09-05 | Yale University, New Haven |
| The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function | NCT07079852 | Not yet recruiting | Phase 1 | 2025-09-01 | University of Texas at Austin, Austin |
| Psilocybin-Assisted Therapy for Intergenerational Trauma | NCT06899165 | Recruiting | Phase 2 | 2025-08-28 | Icahn School of Medicine at Mount Sinai, New York |
| Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD | NCT06349083 | Recruiting | Phase 2 | 2025-08-26 | NYU Langone Health, New Canaan |
| PRoMiSS: Psilocybin and the Role of Music in Set and Setting | NCT07180108 | Recruiting | Phase 1 | 2025-08-12 | Johns Hopkins University, Baltimore |
| The RECAP2 Study: Midazolam and Psilocybin | NCT06692192 | Recruiting | Phase 1 | 2025-08-07 | University of Wisconsin, Madison, Madison |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) | NCT06070649 | Recruiting | Phase 1 | 2025-08-04 | Yale University, New Haven |
| Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) | NCT06760533 | Not yet recruiting | Early Phase 1 | 2025-08-01 | NYU Langone Health, New York |
| Mindfulness-assisted Psychedelic Therapy | NCT06233344 | Recruiting | Phase 2 | 2025-07-30 | University of Southern California, Los Angeles |
| A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression | NCT06597695 | Recruiting | Phase 1 | 2025-07-23 | Massachusetts General Hospital, Chelsea |
| Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality | NCT06706232 | Recruiting | Phase 2 | 2025-07-07 | The University of Texas Health Science Center, Houston, Houston |
| Ketamine, SGB and Combination Treatment for TBI | NCT06608277 | Recruiting | Phase 2 | 2025-07-02 | Northwestern University, Chicago |
| Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial | NCT06405607 | Recruiting | Phase 2 | 2025-06-12 | University of Iowa, Iowa City |
| Dose Optimization of MDMA-Assisted Therapy for PTSD | NCT06418178 | Recruiting | Phase 2 | 2025-06-03 | Bronx VA Medical Center, The Bronx |
| Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | NCT06160284 | Recruiting | Phase 1 | 2025-05-28 | Yale University, New Haven |
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors | NCT06801041 | Recruiting | Phase 2 | 2025-05-23 | M.D. Anderson Cancer Center, Houston |
| Mechanistic Studies of Psilocybin in Headache Disorders | NCT06464367 | Recruiting | Early Phase 1 | 2025-05-19 | Yale University, West Haven |
| Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments | NCT06997549 | Recruiting | Not reported | 2025-05-15 | Neuronetics, Malvern |
| Investigation to Understand and Optimize Psilocybin | NCT06512194 | Recruiting | Phase 2 | 2025-05-13 | Vail Health Behavioral Health, Edwards |
| Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | NCT06656702 | Recruiting | Early Phase 1 | 2025-04-09 | Johns Hopkins University, Baltimore |
| Psilocybin for Methamphetamine Addiction | NCT06899594 | Recruiting | Early Phase 1 | 2025-04-04 | Louisiana State University Health Sciences Center Shreveport, Shreveport |
| Tolerability of MDMA in Schizophrenia | NCT05770375 | Recruiting | Phase 1 | 2025-04-01 | University of California, Los Angeles, Los Angeles |
| Ketamine for Veterans With Parkinson's Disease | NCT06231563 | Recruiting | Phase 2 | 2025-04-01 | VA Office of Research and Development, San Francisco |
| Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans | NCT06671977 | Recruiting | Phase 1 | 2025-03-14 | Yale University, West Haven |
| MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder | NCT05790239 | Recruiting | Phase 2 | 2025-03-01 | VA Greater Los Angeles Healthcare System, Los Angeles |
| Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder | NCT06592833 | Recruiting | Phase 2 | 2025-02-25 | Icahn School of Medicine at Mount Sinai, New York |
| MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | NCT05837845 | Recruiting | Phase 2 | 2025-02-10 | Palo Alto Veterans Institute for Research, Palo Alto |
| Intravenous Ketamine for Treatment-Resistant Depression | NCT06668571 | Recruiting | Phase 2 | 2025-02-10 | Mayo Clinic, Rochester |
| Investigation of Psychedelic Effects in Psychoactive Substances | NCT06772753 | Recruiting | Phase 1 | 2025-02-05 | Johns Hopkins University, Baltimore |
| State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | NCT06888128 | Recruiting | Phase 2 | 2025-01-30 | Baylor College of Medicine, Houston |
| The ENHANCE Study: taVNS and Psilocybin | NCT05866471 | Recruiting | Phase 1 | 2025-01-27 | University of Wisconsin, Madison, Madison |
| PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study | NCT06713616 | Recruiting | Phase 3 | 2025-01-27 | Yale University, Milford |
| Pragmatic Trial of Psilocybin Therapy in Palliative Care | NCT05403086 | Recruiting | Phase 2 | 2025-01-19 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Greenbrae |
| Psilocybin-Assisted Therapy for Physician Well-Being and Burnout | NCT06814522 | Recruiting | Phase 1 | 2025-01-13 | University of California, San Diego, San Diego |
| Psilocybin rTMS for Treatment Resistant Depression | NCT06132178 | Recruiting | Phase 2 | 2025-01-10 | University of Texas at Austin, Austin |
| Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression | NCT06559826 | Recruiting | Phase 2 | 2025-01-10 | Icahn School of Medicine at Mount Sinai, New York |
| Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | NCT06430541 | Recruiting | Phase 1 | 2024-11-21 | University of Colorado, Denver, Aurora |
| Study of Psilocybin for Anorexia in Young Adults | NCT06399263 | Recruiting | Phase 2 | 2024-11-18 | University of California, San Francisco, San Francisco |
| Cognitive Training as an Adjunct to Ketamine in Real-world Clinics | NCT06526078 | Recruiting | Not applicable | 2024-11-12 | University of Pittsburgh, Oakland |
| Psilocybin-assisted Treatment for Cannabis Use Disorder | NCT06660381 | Recruiting | Phase 1 | 2024-11-08 | Johns Hopkins University, Baltimore |
| Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life | NCT06824532 | Recruiting | Not reported | 2024-11-08 | Albany Research Institute, Inc., Albany |
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression | NCT06511908 | Recruiting | Phase 2 | 2024-11-06 | National Institutes of Health Clinical Center (CC), Bethesda |
| Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers | NCT06626139 | Recruiting | Phase 2 | 2024-10-20 | University of California, San Francisco, San Francisco |
| Open-Label Psilocybin Study in Transdiagnostic Population | NCT06442423 | Recruiting | Phase 1 | 2024-10-17 | Yale University, New Haven |
| Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting | NCT06752759 | Recruiting | Phase 3 | 2024-10-16 | Maimonides Medical Center, Brooklyn |
| The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD | NCT06414356 | Recruiting | Phase 4 | 2024-10-02 | Brooke Army Medical Center, San Antonio |
| Psilocybin in Cancer Pain Study | NCT06001749 | Recruiting | Phase 2 | 2024-09-23 | Dana-Farber Cancer Institute, Boston |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | NCT06247839 | Recruiting | Phase 3 | 2024-09-10 | Massachusetts General Hospital, Charlestown |
| Psilocybin Therapy for Depression in Parkinson's Disease | NCT06455293 | Recruiting | Phase 2 | 2024-08-19 | University of California, San Francisco, San Francisco |
| Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department | NCT06085937 | Recruiting | Phase 1 | 2024-05-01 | University of Kansas Medical Center, Kansas City |
| Psilocybin in Chronic Low Back Pain and Depression | NCT06355414 | Recruiting | Phase 1 | 2024-04-22 | Johns Hopkins University, Baltimore |
| MDMA for Co-occurring PTSD and OUD After Childbirth | NCT05219175 | Recruiting | Phase 2 | 2024-04-16 | University of New Mexico, Albuquerque |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | NCT06200155 | Recruiting | Phase 2 | 2024-04-16 | M.D. Anderson Cancer Center, Houston |
| Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain | NCT05265546 | Recruiting | Phase 1 | 2024-03-08 | University of California, Berkeley, Berkeley |
| Ketamine Treatment for PTSD and MDD in TBI | NCT06228391 | Not yet recruiting | Phase 2 | 2024-03-01 | Minneapolis Veterans Affairs Medical Center, Minneapolis |
| Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) | NCT05940324 | Recruiting | Phase 2 | 2024-02-24 | Stanford University, Stanford |
| Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | NCT06067737 | Recruiting | Phase 2 | 2024-02-08 | Johns Hopkins University, Baltimore |
| Neural Circuit Effects of Ketamine in Depression | NCT06213324 | Recruiting | Phase 4 | 2024-01-31 | Icahn School of Medicine at Mount Sinai, New York |
| The OBSERVE Protocol | NCT06725277 | Recruiting | Not reported | 2024-01-21 | Yale University, Milford |
| Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | NCT06480201 | Recruiting | Phase 1 | 2024-01-01 | Baylor College of Medicine, Houston |
| Psilocybin-facilitated Treatment for Chronic Pain | NCT05068791 | Recruiting | Early Phase 1 | 2023-11-01 | University of Alabama at Birmingham, Birmingham |
| 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder | NCT05452772 | Recruiting | Phase 2 | 2023-11-01 | Johns Hopkins University, Birmingham |
| HNC: Human Neural Circuits Electrophysiology During Cognition | NCT05962424 | Recruiting | Phase 1 | 2023-10-05 | Stanford University, Palo Alto |
| RIVER At Home Ketamine Protocols | NCT06070766 | Recruiting | Not reported | 2023-10-01 | RIVER Foundation, Bigfork |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response | NCT05915013 | Recruiting | Phase 1 | 2023-09-07 | Yale University, New Haven |
| Psilocybin Therapy in Advanced Cancer | NCT05398484 | Recruiting | Phase 2 | 2023-05-24 | NYU Langone Health, Aurora |
| The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects | NCT05786066 | Recruiting | Phase 2 | 2023-04-03 | Yale University, West Haven |
| Ketamine & Crisis Response Plan for Suicidal Ideation in the ED | NCT05696691 | Recruiting | Phase 2 | 2023-01-06 | The University of Texas Health Science Center at San Antonio, San Antonio |
| Ketamine Treatment Plans for Chronic Conditions | NCT06038409 | Recruiting | Not reported | 2023-01-01 | RIVER Foundation, Helena |
| Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine | NCT05327699 | Recruiting | Early Phase 1 | 2022-11-08 | Emory University, Atlanta |
| Glutamatergic Mechanisms: Aim2 | NCT05401227 | Recruiting | Phase 1 | 2022-10-15 | New York State Psychiatric Institute, New York |
| Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | NCT05450432 | Recruiting | Phase 4 | 2022-10-13 | Massachusetts General Hospital, Boston |
| MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other | NCT05584826 | Recruiting | Phase 2 | 2022-10-06 | Sunstone Medical, Rockville |
| Ketamine Treatment of Youth Suicide Attempters | NCT04763343 | Recruiting | Phase 3 | 2022-06-27 | The Cleveland Clinic, Boston |
| Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought | NCT05301608 | Recruiting | Phase 1 | 2022-03-03 | Johns Hopkins University, Baltimore |
| Understanding Ketamine's Dissociative Effects (KD Study) | NCT04861051 | Recruiting | Phase 1 | 2021-07-26 | Stanford University, Palo Alto |
| Ketamine Assisted Psychotherapy for Opioid Use Disorder | NCT04892251 | Recruiting | Phase 1 | 2021-05-20 | University of Utah, Salt Lake City |
| Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | NCT04123314 | Recruiting | Early Phase 1 | 2021-03-24 | Johns Hopkins University, Baltimore |
| Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine | NCT04161066 | Recruiting | Phase 1 | 2021-01-13 | University of Wisconsin, Madison, Madison |
| University of Iowa Interventional Psychiatry Service Patient Registry | NCT04480918 | Recruiting | Not reported | 2020-11-02 | University of Iowa, Iowa City |
| Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression | NCT03973268 | Recruiting | Phase 1 | 2020-01-21 | National Institutes of Health Clinical Center (CC), Bethesda |
| Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder | NCT03065335 | Recruiting | Phase 1 | 2017-05-25 | National Institutes of Health Clinical Center (CC), Bethesda |
| Neurobiology of Suicide | NCT02543983 | Recruiting | Phase 2 | 2015-12-01 | National Institutes of Health Clinical Center (CC), Bethesda |
| Ketamine Alcohol (in Treatment-Resistant Depression) | NCT02122562 | Recruiting | Phase 2 | 2014-04-23 | University of Iowa, Iowa City |
At a glance
- 544 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 191 |
| MDMA | 68 |
| LSD | 12 |
| DMT | 10 |
| 5-MeO-DMT | 4 |
| Ketamine | 271 |
| Ibogaine | 4 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 130 | 24% |
| Not yet recruiting | 35 | 6% |
| Enrolling by invitation | 9 | 2% |
| Active, not recruiting | 43 | 8% |
| Completed | 225 | 41% |
| Terminated | 37 | 7% |
| Suspended | 4 | 1% |
| Withdrawn | 38 | 7% |
| Status not reported | 23 | 4% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 41 | 8% |
| Phase 1 | 156 | 29% |
| Phase 2 | 203 | 37% |
| Phase 3 | 44 | 8% |
| Phase 4 | 35 | 6% |
| Not applicable | 34 | 6% |
| Not reported | 31 | 6% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 199 |
| 2020 to 2023 | 153 |
| 2015 to 2019 | 106 |
| 2010 to 2014 | 63 |
| Before 2010 | 22 |
| Start date not reported | 1 |
All counted studies
All 544 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | NCT06005662 | Withdrawn | Phase 2 | 2027-04-01 | Johns Hopkins University, Baltimore |
| Psilocybin for Methamphetamine Use Disorder | NCT07774702 | Not yet recruiting | Phase 2 | 2027-02-01 | University of Alabama at Birmingham, Birmingham |
| Group PACBT for Depression | NCT07566104 | Not yet recruiting | Phase 2 | 2027-01-01 | University of California, Los Angeles, Los Angeles |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life | NCT07719088 | Not yet recruiting | Phase 1 | 2026-12-01 | Vail Health Behavioral Health, Edwards |
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response | NCT07768618 | Not yet recruiting | Phase 2 | 2026-12-01 | Emory University, Atlanta |
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | NCT07833761 | Not yet recruiting | Phase 1 | 2026-12-01 | University of Minnesota, Minneapolis |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV | NCT07756736 | Not yet recruiting | Phase 2 | 2026-11-01 | University of California, San Francisco, San Francisco |
| Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation | NCT07818564 | Recruiting | Phase 1 | 2026-11-01 | Brown University, Providence |
| MDMA-AT for PTSD in Young Adults With Childhood Trauma | NCT07765693 | Not yet recruiting | Phase 2 | 2026-10-31 | Mclean Hospital, Belmont |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | NCT07721467 | Recruiting | Phase 2 | 2026-10-01 | National Institutes of Health Clinical Center (CC), Baltimore |
| Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department | NCT07868913 | Recruiting | Phase 2 | 2026-09-30 | Carl R Darnall Army Medical Center, Fort Hood |
| Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | NCT07810023 | Enrolling by invitation | Not applicable | 2026-09-10 | Endeavor Health, Evanston |
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | NCT07570654 | Recruiting | Phase 2 | 2026-09-01 | COMPASS Pathways, Gilbert |
| Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) | NCT07693257 | Not yet recruiting | Phase 1 | 2026-09-01 | University of California, San Diego, La Jolla |
| The Effects of Psilocybin on Social Connectedness | NCT07693153 | Not yet recruiting | Phase 1 | 2026-08-31 | Yale University, New Haven |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07745569 | Not yet recruiting | Phase 2 | 2026-08-31 | University of New Mexico, Albuquerque |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder | NCT07499583 | Not yet recruiting | Phase 1 | 2026-08-01 | Indiana University, Indianapolis |
| Psilocybin After Trauma Surgery for Pain | NCT07406828 | Not yet recruiting | Phase 1 | 2026-07-01 | University of Pittsburgh, Pittsburgh |
| Anesthesia-Masked Psilocybin Therapy for Major Depression | NCT07479550 | Not yet recruiting | Phase 2 | 2026-07-01 | Stanford University, Stanford |
| Shortened LSD Intervention for Major Depressive Disorder | NCT07503002 | Not yet recruiting | Phase 1 | 2026-07-01 | Johns Hopkins University, Baltimore |
| Psilocybin as a Novel Therapy for Residual Anhedonia | NCT07607938 | Recruiting | Phase 1 | 2026-07-01 | NYU Langone Health, New York |
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment | NCT07610135 | Recruiting | Phase 1 | 2026-07-01 | Johns Hopkins University, Baltimore |
| Biomarker-Guided Antidepressant Selection | NCT07680140 | Recruiting | Phase 4 | 2026-07-01 | Weill Medical College of Cornell University, New York |
| Biomarker Discovery for Suicide Precision Circuit Therapeutics | NCT07723066 | Not yet recruiting | Not reported | 2026-07-01 | Massachusetts General Hospital, Palo Alto |
| Psilocybin Administration With 5-HT1a Blockade | NCT07565493 | Recruiting | Early Phase 1 | 2026-06-15 | Johns Hopkins University, Baltimore |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | NCT07226232 | Recruiting | Phase 3 | 2026-06-01 | VA Office of Research and Development, Birmingham |
| Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain | NCT07306364 | Not yet recruiting | Phase 2 | 2026-06-01 | Yale University, New Haven |
| Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression | NCT07565909 | Not yet recruiting | Phase 2 | 2026-06-01 | University of Washington, Seattle |
| Psilocybin-Assisted Therapy as a Treatment for Depression | NCT07582120 | Not yet recruiting | Phase 2 | 2026-06-01 | Washington University School of Medicine, St Louis |
| Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients | NCT07639359 | Recruiting | Phase 2 | 2026-05-14 | Hospital Italiano de Buenos Aires, Jacksonville |
| NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy | NCT07227909 | Not yet recruiting | Phase 2 | 2026-05-04 | M.D. Anderson Cancer Center, Houston |
| Morphine or Ketamine for Analgesia | NCT06835504 | Not yet recruiting | Phase 3 | 2026-05-01 | Columbia University, Los Angeles |
| Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder | NCT07296094 | Not yet recruiting | Phase 2 | 2026-05-01 | Brigham and Women's Hospital, Boston |
| Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07484906 | Withdrawn | Phase 2 | 2026-05-01 | University of New Mexico, Albuquerque |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | NCT07506395 | Recruiting | Phase 1 | 2026-05-01 | University of New Mexico, Albuquerque |
| MDMA Assisted Therapy for BN | NCT07542145 | Recruiting | Phase 1 | 2026-05-01 | Icahn School of Medicine at Mount Sinai, New York |
| MDMA Therapy in Veterans With PTSD | NCT07569159 | Recruiting | Phase 2 | 2026-05-01 | Sunstone Medical, Rockville |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease | NCT07610369 | Recruiting | Phase 2 | 2026-05-01 | Yale University, New Haven |
| Study of Midomafetamine in Healthy Adults | NCT07584720 | Active, not recruiting | Phase 1 | 2026-04-23 | Resilient Pharmaceuticals, Overland Park |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | NCT07118839 | Recruiting | Phase 2 | 2026-04-15 | VA Office of Research and Development, West Haven |
| MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers | NCT05455996 | Not yet recruiting | Phase 2 | 2026-04-01 | Nautilus Sanctuary, Boulder |
| MDMA-assisted Therapy for Fibromyalgia | NCT06066853 | Recruiting | Early Phase 1 | 2026-04-01 | Spaulding Rehabilitation Hospital, Charlestown |
| Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | NCT07336238 | Active, not recruiting | Phase 2 | 2026-04-01 | University of Washington, Seattle |
| Psilocybin Microdosing on Cognition, Mood and Quality of Life | NCT07449351 | Not yet recruiting | Early Phase 1 | 2026-04-01 | Yale University, Hartford |
| Safety and Tolerability Trial of Psilocybin in Healthy Older Adults | NCT07516405 | Recruiting | Phase 1 | 2026-04-01 | University of Colorado, Denver, San Francisco |
| Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects | NCT07540494 | Completed | Phase 1 | 2026-04-01 | GH Research Ireland Limited, Miami |
| KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury | NCT07563296 | Recruiting | Phase 2 | 2026-04-01 | University of Utah, Salt Lake City |
| Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression | NCT07563868 | Recruiting | Not applicable | 2026-04-01 | Massachusetts General Hospital, Boston |
| MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | NCT03606538 | Not yet recruiting | Phase 1 | 2026-03-29 | Lykos Therapeutics, Knoxville |
| ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1 | NCT07528014 | Recruiting | Not reported | 2026-03-25 | Salma Health, Inc., La Jolla |
| Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids | NCT06827054 | Not yet recruiting | Phase 2 | 2026-03-15 | Roswell Park Cancer Institute, Buffalo |
| Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) | NCT06378528 | Suspended | Early Phase 1 | 2026-03-01 | University of Wisconsin, Madison, Madison |
| Psilocybin for Prolonged Grief Disorder | NCT06724289 | Recruiting | Early Phase 1 | 2026-03-01 | University of Virginia, Charlottesville |
| Psilocybin-Assisted Randomized Therapy | NCT07332143 | Recruiting | Phase 2 | 2026-03-01 | Emory University, Atlanta |
| A Study of Psychedelics in Healthy Older Adults With Low Well-being | NCT07386730 | Recruiting | Phase 1 | 2026-03-01 | University of California, San Francisco, San Francisco |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | NCT07053917 | Recruiting | Phase 1 | 2026-02-09 | Johns Hopkins University, Baltimore |
| A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders | NCT04454684 | Withdrawn | Phase 2 | 2026-02-01 | Lykos Therapeutics, Torrance |
| Safety Profile of Psilocybin for Cocaine Use Disorder | NCT06102434 | Suspended | Early Phase 1 | 2026-02-01 | University of California, Los Angeles, Los Angeles |
| Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | NCT06788249 | Recruiting | Early Phase 1 | 2026-02-01 | University of Pennsylvania, Philadelphia |
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | NCT07139106 | Not yet recruiting | Phase 4 | 2026-02-01 | New York State Psychiatric Institute, New York |
| Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study | NCT07360301 | Not yet recruiting | Phase 1 | 2026-02-01 | University of Wisconsin, Madison, Madison |
| Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement | NCT07369089 | Not yet recruiting | Phase 2 | 2026-02-01 | University of California, San Diego, La Jolla |
| Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter | NCT07296328 | Not yet recruiting | Phase 2 | 2026-01-15 | NYU Langone Health, New York |
| Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation | NCT07396220 | Enrolling by invitation | Not applicable | 2026-01-09 | University of California, San Diego, San Diego |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | NCT07227454 | Recruiting | Phase 3 | 2026-01-08 | Janssen Research & Development, LLC, Atlanta |
| RCT of Psilocybin-assisted CBT for Depression | NCT07281352 | Recruiting | Phase 1 | 2026-01-05 | University of California, Los Angeles, Los Angeles |
| Ketamine for Opioid Use Disorder | NCT06943859 | Recruiting | Phase 2 | 2026-01-01 | University of Maryland, Baltimore, Baltimore |
| Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study | NCT06988319 | Recruiting | Phase 1 | 2026-01-01 | Oregon Health and Science University, Portland |
| Psilocybin for Treatment of OCD-2 | NCT06992999 | Not yet recruiting | Phase 1 | 2026-01-01 | University of Arizona, Tucson |
| MDMA-Assisted Therapy for Mental Healthcare Providers | NCT07102576 | Recruiting | Phase 1 | 2026-01-01 | Icahn School of Medicine at Mount Sinai, New York |
| Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer | NCT07216404 | Recruiting | Phase 2 | 2026-01-01 | Ohio State University Comprehensive Cancer Center, Columbus |
| Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression | NCT07247006 | Not yet recruiting | Phase 2 | 2026-01-01 | University of Rochester, Rochester |
| Psilocybin to Treat Depression in Spinal Cord Injury | NCT07251491 | Recruiting | Phase 1 | 2026-01-01 | James J. Peters Veterans Affairs Medical Center, The Bronx |
| MDMA-Assisted Massed Exposure Therapy for PTSD | NCT07288151 | Recruiting | Phase 2 | 2026-01-01 | Emory University, Atlanta |
| Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. | NCT07347405 | Recruiting | Phase 1 | 2026-01-01 | University of Arizona, Phoenix |
| Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults | NCT07369024 | Recruiting | Phase 2 | 2026-01-01 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance |
| Psilocybin on Brain Mechanisms of Motivation in OUD | NCT06810310 | Recruiting | Phase 2 | 2025-12-22 | University of Pennsylvania, Philadelphia |
| Ketamine Biomarker Validation | NCT07307768 | Not yet recruiting | Phase 1 | 2025-12-20 | Soterix Medical, New York |
| Psilocybin for Opioid Use Disorder (OUD) | NCT06796062 | Recruiting | Phase 2 | 2025-12-17 | NYU Langone Health, Albuquerque |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | NCT06793397 | Recruiting | Phase 3 | 2025-12-10 | Cybin IRL Limited, Birmingham |
| Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression | NCT06419439 | Recruiting | Phase 2 | 2025-12-03 | VA Office of Research and Development, Ann Arbor |
| A Phase 2A Trial of DT402 for Autism Spectrum Disorder | NCT07303907 | Recruiting | Phase 2 | 2025-12-03 | Definium Therapeutics US, Inc., New York |
| Imaging Depression in Parkinson's Disease | NCT06402955 | Recruiting | Phase 2 | 2025-12-01 | Yale University, New Haven |
| Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD | NCT06902974 | Recruiting | Phase 2 | 2025-12-01 | Sunstone Medical, Rockville |
| Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD | NCT07275970 | Active, not recruiting | Phase 1 | 2025-12-01 | Scottsdale Research Institute, Scottsdale |
| Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults | NCT06367738 | Recruiting | Phase 1 | 2025-11-01 | University of California, Berkeley, Berkeley |
| A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety | NCT06820723 | Recruiting | Phase 2 | 2025-11-01 | Ohio State University, Columbus |
| The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series | NCT06048263 | Withdrawn | Phase 2 | 2025-10-15 | Washington University School of Medicine, St Louis |
| Wellcome Leap Psilocybin for OUD | NCT06786325 | Recruiting | Phase 2 | 2025-10-07 | University of Pennsylvania, Philadelphia |
| Psilocybin as a Treatment for Chronic Pain in Smokers | NCT07118332 | Recruiting | Early Phase 1 | 2025-10-01 | Yale University, West Haven |
| Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | NCT06989957 | Recruiting | Phase 1 | 2025-09-17 | Johns Hopkins University, Baltimore |
| MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | NCT05783817 | Recruiting | Phase 2 | 2025-09-10 | Stanford University, Palo Alto |
| Mapping Ibogaine Neural Dynamics in Opioid Use Disorder | NCT07226570 | Recruiting | Not reported | 2025-09-08 | University of California, Irvine, Irvine |
| MDMA in Borderline Personality Disorder | NCT06683014 | Recruiting | Phase 2 | 2025-09-05 | Yale University, New Haven |
| Trifecta Research Study | NCT06810765 | Withdrawn | Phase 2 | 2025-09-01 | Johns Hopkins University, Baltimore |
| The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function | NCT07079852 | Not yet recruiting | Phase 1 | 2025-09-01 | University of Texas at Austin, Austin |
| Psilocybin-Assisted Therapy for Intergenerational Trauma | NCT06899165 | Recruiting | Phase 2 | 2025-08-28 | Icahn School of Medicine at Mount Sinai, New York |
| Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD | NCT06349083 | Recruiting | Phase 2 | 2025-08-26 | NYU Langone Health, New Canaan |
| PRoMiSS: Psilocybin and the Role of Music in Set and Setting | NCT07180108 | Recruiting | Phase 1 | 2025-08-12 | Johns Hopkins University, Baltimore |
| The RECAP2 Study: Midazolam and Psilocybin | NCT06692192 | Recruiting | Phase 1 | 2025-08-07 | University of Wisconsin, Madison, Madison |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) | NCT06070649 | Recruiting | Phase 1 | 2025-08-04 | Yale University, New Haven |
| Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) | NCT06760533 | Not yet recruiting | Early Phase 1 | 2025-08-01 | NYU Langone Health, New York |
| Mindfulness-assisted Psychedelic Therapy | NCT06233344 | Recruiting | Phase 2 | 2025-07-30 | University of Southern California, Los Angeles |
| A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression | NCT06597695 | Recruiting | Phase 1 | 2025-07-23 | Massachusetts General Hospital, Chelsea |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | NCT06605105 | Enrolling by invitation | Phase 3 | 2025-07-18 | Cybin IRL Limited, Phoenix |
| Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality | NCT06706232 | Recruiting | Phase 2 | 2025-07-07 | The University of Texas Health Science Center, Houston, Houston |
| Ketamine, SGB and Combination Treatment for TBI | NCT06608277 | Recruiting | Phase 2 | 2025-07-02 | Northwestern University, Chicago |
| MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | NCT06353282 | Withdrawn | Phase 2 | 2025-07-01 | University of California, Los Angeles, Los Angeles |
| Drug Effects on Mood and Behavior - Expectancy | NCT07061886 | Completed | Early Phase 1 | 2025-06-26 | University of Chicago, Chicago |
| Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial | NCT06405607 | Recruiting | Phase 2 | 2025-06-12 | University of Iowa, Iowa City |
| Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder) | NCT06795659 | Completed | Phase 1 | 2025-06-09 | The University of Texas Health Science Center at San Antonio, San Antonio |
| Mood Effects of Serotonin Agonists: Depression | NCT07017478 | Completed | Early Phase 1 | 2025-06-09 | University of Chicago, Chicago |
| Ketamine Effects on Learning In Eating Disorders | NCT06736769 | Enrolling by invitation | Phase 2 | 2025-06-05 | University of California, San Francisco, San Francisco |
| Dose Optimization of MDMA-Assisted Therapy for PTSD | NCT06418178 | Recruiting | Phase 2 | 2025-06-03 | Bronx VA Medical Center, The Bronx |
| Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) | NCT06853912 | Active, not recruiting | Phase 2 | 2025-06-01 | University of Washington, Seattle |
| Psilocybin With Intracranial Neural Sensing | NCT06919640 | Enrolling by invitation | Phase 1 | 2025-06-01 | University of California, San Francisco, San Francisco |
| Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | NCT06160284 | Recruiting | Phase 1 | 2025-05-28 | Yale University, New Haven |
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors | NCT06801041 | Recruiting | Phase 2 | 2025-05-23 | M.D. Anderson Cancer Center, Houston |
| Mechanistic Studies of Psilocybin in Headache Disorders | NCT06464367 | Recruiting | Early Phase 1 | 2025-05-19 | Yale University, West Haven |
| Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments | NCT06997549 | Recruiting | Not reported | 2025-05-15 | Neuronetics, Malvern |
| Investigation to Understand and Optimize Psilocybin | NCT06512194 | Recruiting | Phase 2 | 2025-05-13 | Vail Health Behavioral Health, Edwards |
| Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 | NCT06821087 | Completed | Phase 2 | 2025-04-28 | University of Texas at Austin, Austin |
| Psilocybin Brain Stimulation and Imaging Pilot Study | NCT06835699 | Completed | Phase 1 | 2025-04-18 | Johns Hopkins University, Baltimore |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | NCT06941844 | Active, not recruiting | Phase 3 | 2025-04-14 | Definium Therapeutics, Fayetteville |
| Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | NCT06656702 | Recruiting | Early Phase 1 | 2025-04-09 | Johns Hopkins University, Baltimore |
| Psilocybin for Methamphetamine Addiction | NCT06899594 | Recruiting | Early Phase 1 | 2025-04-04 | Louisiana State University Health Sciences Center Shreveport, Shreveport |
| Tolerability of MDMA in Schizophrenia | NCT05770375 | Recruiting | Phase 1 | 2025-04-01 | University of California, Los Angeles, Los Angeles |
| Ketamine for Veterans With Parkinson's Disease | NCT06231563 | Recruiting | Phase 2 | 2025-04-01 | VA Office of Research and Development, San Francisco |
| Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans | NCT06671977 | Recruiting | Phase 1 | 2025-03-14 | Yale University, West Haven |
| Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism | NCT07189988 | Active, not recruiting | Not reported | 2025-03-05 | Healing Advocacy Fund, Portland |
| MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder | NCT05790239 | Recruiting | Phase 2 | 2025-03-01 | VA Greater Los Angeles Healthcare System, Los Angeles |
| Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder | NCT06592833 | Recruiting | Phase 2 | 2025-02-25 | Icahn School of Medicine at Mount Sinai, New York |
| Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions | NCT06823024 | Enrolling by invitation | Not reported | 2025-02-18 | Psyrin Inc., Sunnyvale |
| MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | NCT05837845 | Recruiting | Phase 2 | 2025-02-10 | Palo Alto Veterans Institute for Research, Palo Alto |
| Intravenous Ketamine for Treatment-Resistant Depression | NCT06668571 | Recruiting | Phase 2 | 2025-02-10 | Mayo Clinic, Rochester |
| Investigation of Psychedelic Effects in Psychoactive Substances | NCT06772753 | Recruiting | Phase 1 | 2025-02-05 | Johns Hopkins University, Baltimore |
| State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | NCT06888128 | Recruiting | Phase 2 | 2025-01-30 | Baylor College of Medicine, Houston |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | NCT06809595 | Active, not recruiting | Phase 3 | 2025-01-29 | Definium Therapeutics US, Inc., Little Rock |
| The ENHANCE Study: taVNS and Psilocybin | NCT05866471 | Recruiting | Phase 1 | 2025-01-27 | University of Wisconsin, Madison, Madison |
| PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study | NCT06713616 | Recruiting | Phase 3 | 2025-01-27 | Yale University, Milford |
| Pragmatic Trial of Psilocybin Therapy in Palliative Care | NCT05403086 | Recruiting | Phase 2 | 2025-01-19 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Greenbrae |
| Psilocybin-Assisted Therapy for Physician Well-Being and Burnout | NCT06814522 | Recruiting | Phase 1 | 2025-01-13 | University of California, San Diego, San Diego |
| Psilocybin rTMS for Treatment Resistant Depression | NCT06132178 | Recruiting | Phase 2 | 2025-01-10 | University of Texas at Austin, Austin |
| Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression | NCT06559826 | Recruiting | Phase 2 | 2025-01-10 | Icahn School of Medicine at Mount Sinai, New York |
| Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder | NCT05562973 | Withdrawn | Phase 1 | 2025-01-01 | Johns Hopkins University, Baltimore |
| Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome | NCT06698848 | Active, not recruiting | Phase 1 | 2025-01-01 | Massachusetts General Hospital, Boston |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | NCT06564818 | Active, not recruiting | Phase 3 | 2024-12-17 | Cybin IRL Limited, Phoenix |
| Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics | NCT06624137 | Terminated | Not reported | 2024-12-12 | Yale University, Hamden |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | NCT06741228 | Active, not recruiting | Phase 3 | 2024-12-11 | Definium Therapeutics US, Inc., Gilbert |
| Safety for Home Administration of Microdose Psilocybin Use | NCT06450210 | Completed | Phase 1 | 2024-12-06 | Johns Hopkins University, Baltimore |
| Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2) | NCT04073433 | Withdrawn | Phase 1 | 2024-12-01 | Lykos Therapeutics, Torrance |
| Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | NCT06430541 | Recruiting | Phase 1 | 2024-11-21 | University of Colorado, Denver, Aurora |
| A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | NCT06644170 | Completed | Phase 1 | 2024-11-19 | University of Washington, Seattle |
| Study of Psilocybin for Anorexia in Young Adults | NCT06399263 | Recruiting | Phase 2 | 2024-11-18 | University of California, San Francisco, San Francisco |
| Cognitive Training as an Adjunct to Ketamine in Real-world Clinics | NCT06526078 | Recruiting | Not applicable | 2024-11-12 | University of Pittsburgh, Oakland |
| FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression | NCT06620042 | Completed | Phase 2 | 2024-11-12 | The Cleveland Clinic, Cleveland |
| Psilocybin-assisted Treatment for Cannabis Use Disorder | NCT06660381 | Recruiting | Phase 1 | 2024-11-08 | Johns Hopkins University, Baltimore |
| Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life | NCT06824532 | Recruiting | Not reported | 2024-11-08 | Albany Research Institute, Inc., Albany |
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression | NCT06511908 | Recruiting | Phase 2 | 2024-11-06 | National Institutes of Health Clinical Center (CC), Bethesda |
| Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment | NCT06069843 | Active, not recruiting | Phase 2 | 2024-11-01 | Icahn School of Medicine at Mount Sinai, New York |
| MDMA-assisted Massed Prolonged Exposure for PTSD | NCT06117306 | Active, not recruiting | Phase 3 | 2024-10-25 | San Diego Veterans Healthcare System, San Diego |
| Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers | NCT06626139 | Recruiting | Phase 2 | 2024-10-20 | University of California, San Francisco, San Francisco |
| Open-Label Psilocybin Study in Transdiagnostic Population | NCT06442423 | Recruiting | Phase 1 | 2024-10-17 | Yale University, New Haven |
| Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting | NCT06752759 | Recruiting | Phase 3 | 2024-10-16 | Maimonides Medical Center, Brooklyn |
| The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD | NCT06414356 | Recruiting | Phase 4 | 2024-10-02 | Brooke Army Medical Center, San Antonio |
| Optimizing Microdosing and Meditation | NCT06560658 | Withdrawn | Not applicable | 2024-10-01 | National University of Natural Medicine, Portland |
| Psilocybin in Cancer Pain Study | NCT06001749 | Recruiting | Phase 2 | 2024-09-23 | Dana-Farber Cancer Institute, Boston |
| Ketamine for Methamphetamine Use Disorder | NCT06496750 | Active, not recruiting | Phase 2 | 2024-09-11 | University of Texas Southwestern Medical Center, Albuquerque |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | NCT06247839 | Recruiting | Phase 3 | 2024-09-10 | Massachusetts General Hospital, Charlestown |
| MDMA-Assisted Therapy for Pathological Narcissism | NCT06565494 | Active, not recruiting | Early Phase 1 | 2024-08-27 | University of Washington, Seattle |
| Psilocybin Therapy for Depression in Parkinson's Disease | NCT06455293 | Recruiting | Phase 2 | 2024-08-19 | University of California, San Francisco, San Francisco |
| Low-Income Group Psilocybin Assisted Therapy for Depression | NCT06372197 | Completed | Not applicable | 2024-08-01 | National University of Natural Medicine, Portland |
| Role Of Non-Specific Effects in The Treatment of Depression With Esketamine | NCT05910775 | Terminated | Not applicable | 2024-07-13 | Yale University, New Haven |
| Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment | NCT06139016 | Completed | Not applicable | 2024-07-11 | Yale University, New Haven |
| Psilocybin for Treatment-Resistant Depression | NCT06230757 | Completed | Phase 2 | 2024-07-08 | University of Colorado, Denver, Aurora |
| Ketamine for OUD and Suicidal Ideation in the ED | NCT06111339 | Terminated | Phase 2 | 2024-06-14 | Brigham and Women's Hospital, Boston |
| A Study of Psilocybin for PTSD | NCT06407635 | Active, not recruiting | Phase 1 | 2024-06-07 | Johns Hopkins University, Baltimore |
| Ketamine-assisted Therapy for Advanced GI Cancer | NCT06077487 | Terminated | Phase 4 | 2024-05-17 | University of California, San Francisco, San Francisco |
| A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) | NCT06051721 | Completed | Phase 2 | 2024-05-10 | Cybin IRL Limited, Hollywood |
| The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. | NCT03752918 | Withdrawn | Phase 1 | 2024-05-01 | Yale University, New Haven |
| Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department | NCT06085937 | Recruiting | Phase 1 | 2024-05-01 | University of Kansas Medical Center, Kansas City |
| Psilocybin in Chronic Low Back Pain and Depression | NCT06355414 | Recruiting | Phase 1 | 2024-04-22 | Johns Hopkins University, Baltimore |
| Psilocybin-Assisted Therapy in Treatment-Resistant Depression | NCT06303739 | Active, not recruiting | Phase 3 | 2024-04-19 | University of North Carolina, Chapel Hill, Chapel Hill |
| MDMA for Co-occurring PTSD and OUD After Childbirth | NCT05219175 | Recruiting | Phase 2 | 2024-04-16 | University of New Mexico, Albuquerque |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | NCT06200155 | Recruiting | Phase 2 | 2024-04-16 | M.D. Anderson Cancer Center, Houston |
| A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder | NCT06340958 | Completed | Phase 2 | 2024-03-18 | Clexio Biosciences Ltd., La Jolla |
| Psilocybin for Major Depressive Disorder (MDD) | NCT06308653 | Active, not recruiting | Phase 3 | 2024-03-13 | Usona Institute, Birmingham |
| Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain | NCT05265546 | Recruiting | Phase 1 | 2024-03-08 | University of California, Berkeley, Berkeley |
| Ketamine Treatment for PTSD and MDD in TBI | NCT06228391 | Not yet recruiting | Phase 2 | 2024-03-01 | Minneapolis Veterans Affairs Medical Center, Minneapolis |
| Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) | NCT05940324 | Recruiting | Phase 2 | 2024-02-24 | Stanford University, Stanford |
| MDMA Plus Exposure Therapy for PTSD | NCT05746572 | Enrolling by invitation | Phase 2 | 2024-02-13 | Emory University, Atlanta |
| Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | NCT06067737 | Recruiting | Phase 2 | 2024-02-08 | Johns Hopkins University, Baltimore |
| MDMA for AUD/PTSD Comorbidity | NCT05943665 | Completed | Phase 2 | 2024-02-06 | Brown University, Providence |
| Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder | NCT05421065 | Active, not recruiting | Phase 2 | 2024-02-02 | University of Iowa, Iowa City |
| Neural Circuit Effects of Ketamine in Depression | NCT06213324 | Recruiting | Phase 4 | 2024-01-31 | Icahn School of Medicine at Mount Sinai, New York |
| The OBSERVE Protocol | NCT06725277 | Recruiting | Not reported | 2024-01-21 | Yale University, Milford |
| Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) | NCT06206265 | Active, not recruiting | Phase 2 | 2024-01-17 | TRYP Therapeutics, Boston |
| Psilocybin for Major Depressive Disorder | NCT05675800 | Withdrawn | Phase 2 | 2024-01-01 | Washington University School of Medicine, St Louis |
| Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | NCT06480201 | Recruiting | Phase 1 | 2024-01-01 | Baylor College of Medicine, Houston |
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD | NCT06036511 | Withdrawn | Phase 1 | 2023-12-31 | University of New Mexico, Albuquerque |
| Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use | NCT05242029 | Withdrawn | Phase 2 | 2023-12-01 | Johns Hopkins University, Baltimore |
| Psilocybin Therapy for Chronic Low Back Pain | NCT05351541 | Active, not recruiting | Phase 1 | 2023-12-01 | University of California, San Francisco, San Francisco |
| Consciousness, Psilocybin, and Well-Being | NCT05592379 | Completed | Phase 1 | 2023-11-07 | University of Wisconsin, Madison, Madison |
| Psilocybin-facilitated Treatment for Chronic Pain | NCT05068791 | Recruiting | Early Phase 1 | 2023-11-01 | University of Alabama at Birmingham, Birmingham |
| Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder | NCT05399498 | Completed | Phase 2 | 2023-11-01 | University of Chicago, Chicago |
| 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder | NCT05452772 | Recruiting | Phase 2 | 2023-11-01 | Johns Hopkins University, Birmingham |
| Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress | NCT05344625 | Withdrawn | Early Phase 1 | 2023-10-31 | Northwell Health, Manhasset |
| VA Aripiprazole vs Esketamine for Treatment Resistant Depression | NCT05554627 | Withdrawn | Phase 4 | 2023-10-27 | VA Office of Research and Development, Tuscaloosa |
| Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer | NCT05947383 | Active, not recruiting | Phase 2 | 2023-10-23 | Sunstone Medical, Rockville |
| MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD | NCT05979844 | Completed | Phase 3 | 2023-10-06 | San Diego Veterans Healthcare System, San Diego |
| HNC: Human Neural Circuits Electrophysiology During Cognition | NCT05962424 | Recruiting | Phase 1 | 2023-10-05 | Stanford University, Palo Alto |
| KET-RO Plus RO DBT for Treatment Resistant Depression | NCT06138691 | Completed | Phase 1 | 2023-10-04 | Washington University School of Medicine, St Louis |
| Group MDMA-therapy for Veterans With PTSD | NCT05961527 | Completed | Phase 1 | 2023-10-01 | Portland VA Research Foundation, Inc, Vancouver |
| Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan | NCT06034821 | Enrolling by invitation | Phase 4 | 2023-10-01 | Brigham and Women's Hospital, San Francisco |
| RIVER At Home Ketamine Protocols | NCT06070766 | Recruiting | Not reported | 2023-10-01 | RIVER Foundation, Bigfork |
| Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia | NCT05128162 | Completed | Phase 2 | 2023-09-27 | University of Michigan, Ann Arbor |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response | NCT05915013 | Recruiting | Phase 1 | 2023-09-07 | Yale University, New Haven |
| Northwest Therapies Trauma Psilocybin Study Compassionate Use Study | NCT05042466 | Status not reported | Phase 1 | 2023-09-03 | NWTraumatherapies, Bozeman |
| Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans | NCT05173831 | Withdrawn | Phase 2 | 2023-09-01 | Lykos Therapeutics, Torrance |
| Ketamine for the Treatment for Alcohol Use Disorder in the ED | NCT05661669 | Withdrawn | Phase 2 | 2023-09-01 | Brigham and Women's Hospital, Boston |
| Enhancing Week-long Psychological Treatment for PTSD With Ketamine | NCT05737693 | Active, not recruiting | Phase 2 | 2023-08-21 | Yale University, New Haven |
| Exploratory Study of Low Dose Psilocybin | NCT05227742 | Withdrawn | Early Phase 1 | 2023-08-15 | University of Alabama at Birmingham, Birmingham |
| Neural and Physiological Correlates of Psychedelic Sub-states | NCT05698511 | Active, not recruiting | Phase 1 | 2023-07-31 | University of California, San Francisco, San Francisco |
| Prosocial Effects of MDMA | NCT05948683 | Completed | Early Phase 1 | 2023-07-21 | University of Chicago, Chicago |
| Effects of Repeated Psilocybin Dosing in OCD | NCT05370911 | Active, not recruiting | Phase 1 | 2023-07-20 | Yale University, New Haven |
| Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort | NCT05855876 | Status not reported | Not reported | 2023-07-05 | Stella Center, Westmont |
| Brain Network Dynamics of Depression During Esketamine Treatment | NCT06012916 | Completed | Not reported | 2023-07-03 | University of North Carolina, Chapel Hill, Chapel Hill |
| PET Synaptogenesis After Psilocybin In DEpression Recovery | NCT05601648 | Withdrawn | Phase 2 | 2023-07-01 | Washington University School of Medicine, St Louis |
| Psilocybin-assisted CBT for Depression | NCT05227612 | Completed | Phase 1 | 2023-06-27 | University of California, Los Angeles, Los Angeles |
| Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | NCT05847686 | Completed | Phase 1 | 2023-06-27 | University of Washington, Seattle |
| Bioavailability Study of Psilocybin in Normal Adults | NCT05467761 | Withdrawn | Phase 1 | 2023-06-01 | University of Wisconsin, Madison, Madison |
| Psilocybin Therapy in Advanced Cancer | NCT05398484 | Recruiting | Phase 2 | 2023-05-24 | NYU Langone Health, Aurora |
| Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | NCT05220046 | Completed | Phase 1 | 2023-04-10 | University of Nebraska, Omaha |
| The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects | NCT05786066 | Recruiting | Phase 2 | 2023-04-03 | Yale University, West Haven |
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder | NCT05322954 | Terminated | Phase 1 | 2023-03-03 | University of Wisconsin, Madison, Madison |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | NCT05711940 | Active, not recruiting | Phase 3 | 2023-02-14 | COMPASS Pathways, Gilbert |
| Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment | NCT05719909 | Suspended | Not applicable | 2023-02-14 | University of Pittsburgh, Pittsburgh |
| [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine | NCT05522673 | Terminated | Phase 1 | 2023-02-08 | National Institutes of Health Clinical Center (CC), Bethesda |
| A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | NCT05733546 | Active, not recruiting | Phase 2 | 2023-01-30 | COMPASS Pathways, La Jolla |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | NCT05624268 | Completed | Phase 3 | 2023-01-19 | COMPASS Pathways, Tucson |
| Ketamine & Crisis Response Plan for Suicidal Ideation in the ED | NCT05696691 | Recruiting | Phase 2 | 2023-01-06 | The University of Texas Health Science Center at San Antonio, San Antonio |
| PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout | NCT05557643 | Completed | Phase 1 | 2023-01-02 | University of Utah, Salt Lake City |
| Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder | NCT05554094 | Active, not recruiting | Phase 2 | 2023-01-01 | Ohio State University, Columbus |
| Ketamine Treatment Plans for Chronic Conditions | NCT06038409 | Recruiting | Not reported | 2023-01-01 | RIVER Foundation, Helena |
| Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers | NCT05698095 | Completed | Phase 1 | 2022-12-27 | Usona Institute, Overland Park |
| Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression | NCT05615948 | Completed | Phase 4 | 2022-12-06 | Maimonides Medical Center, Brooklyn |
| Effects of Psilocybin in Obsessive Compulsive Disorder | NCT05546658 | Active, not recruiting | Early Phase 1 | 2022-11-28 | Johns Hopkins University, Baltimore |
| Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine | NCT05327699 | Recruiting | Early Phase 1 | 2022-11-08 | Emory University, Atlanta |
| Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain | NCT05506982 | Completed | Phase 1 | 2022-11-01 | Emory University, Atlanta |
| Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer | NCT05086250 | Completed | Early Phase 1 | 2022-10-20 | Cedars-Sinai Medical Center, Los Angeles |
| Glutamatergic Mechanisms: Aim2 | NCT05401227 | Recruiting | Phase 1 | 2022-10-15 | New York State Psychiatric Institute, New York |
| Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | NCT05450432 | Recruiting | Phase 4 | 2022-10-13 | Massachusetts General Hospital, Boston |
| Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | NCT05481736 | Completed | Phase 2 | 2022-10-12 | COMPASS Pathways, San Diego |
| MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other | NCT05584826 | Recruiting | Phase 2 | 2022-10-06 | Sunstone Medical, Rockville |
| Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents | NCT04592809 | Completed | Phase 3 | 2022-10-03 | University of Texas Southwestern Medical Center, Dallas |
| Psilocybin-assisted Therapy for Phantom Limb Pain | NCT05224336 | Active, not recruiting | Phase 1 | 2022-10-03 | University of California, San Diego, San Diego |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD | NCT05381974 | Withdrawn | Phase 2 | 2022-09-15 | Massachusetts General Hospital, Charlestown |
| A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression | NCT05268497 | Withdrawn | Phase 1 | 2022-09-01 | Janssen Research & Development, LLC, New Haven |
| A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms | NCT05407064 | Completed | Phase 2 | 2022-08-24 | Definium Therapeutics, Little Rock |
| Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD | NCT05895318 | Completed | Not reported | 2022-08-08 | Albany Research Institute, Inc., Albany |
| A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder | NCT05385783 | Completed | Phase 1 | 2022-08-02 | Cybin IRL Limited, Atlanta |
| Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | NCT04968938 | Withdrawn | Phase 2 | 2022-08-01 | Lykos Therapeutics, Torrance |
| Trifecta Research Study | NCT07717866 | Active, not recruiting | Not reported | 2022-08-01 | Axial Therapeutic Research, Northridge |
| Food Effects on Bioavailability of MDMA in Healthy Volunteers | NCT05147402 | Completed | Phase 1 | 2022-07-28 | Lykos Therapeutics, Knoxville |
| Anhedonia, Development, and Emotions: Phenotyping and Therapeutics | NCT05487885 | Completed | Phase 4 | 2022-07-22 | University of Pittsburgh, Pittsburgh |
| Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder | NCT04982796 | Active, not recruiting | Phase 1 | 2022-07-07 | Portland VA Research Foundation, Inc, Vancouver |
| Effects of Psilocybin in Post-Treatment Lyme Disease | NCT05305105 | Completed | Phase 1 | 2022-07-01 | Johns Hopkins University, Baltimore |
| Ketamine Treatment of Youth Suicide Attempters | NCT04763343 | Recruiting | Phase 3 | 2022-06-27 | The Cleveland Clinic, Boston |
| An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics | NCT05478278 | Completed | Phase 1 | 2022-06-22 | Usona Institute, Overland Park |
| The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | NCT05312151 | Completed | Phase 2 | 2022-06-10 | COMPASS Pathways, Rockville |
| Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | NCT04928703 | Completed | Early Phase 1 | 2022-05-26 | ERP Biomarker Qualification Consortium, Marlton |
| Comparing the Effects of Psilocin and Psilocybin in Healthy Adults | NCT05317689 | Status not reported | Phase 1 | 2022-05-26 | University of California, San Francisco, San Francisco |
| Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function | NCT05379959 | Completed | Early Phase 1 | 2022-05-11 | University of Chicago, Chicago |
| Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets | NCT05046184 | Completed | Phase 2 | 2022-05-05 | University of Texas Southwestern Medical Center, Dallas |
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy | NCT05214417 | Status not reported | Phase 2 | 2022-05-01 | The Ketamine Research Foundation, San Anselmo |
| Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial | NCT05233566 | Completed | Phase 3 | 2022-04-25 | Washington University School of Medicine, St Louis |
| Social Anxiety MDMA-Assisted Therapy Investigation | NCT05138068 | Completed | Phase 2 | 2022-04-13 | Portland Psychotherapy Clinic, Research, and Training Center, Portland |
| Effect of Ketamine and Etomidate During RSI on Long Term Outcomes | NCT06179485 | Enrolling by invitation | Not reported | 2022-04-06 | Vanderbilt University Medical Center, Birmingham |
| Ketamine for OUD and Comorbid Depression (OUDCD) | NCT05051449 | Terminated | Phase 1 | 2022-04-04 | University of Maryland, Baltimore, Baltimore |
| Ketamine and Epigenetic Aging | NCT05294835 | Status not reported | Phase 2 | 2022-04-01 | TruDiagnostic, Lexington |
| Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study | NCT05950711 | Active, not recruiting | Phase 4 | 2022-03-30 | Ohio State University, Columbus |
| The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation | NCT05220410 | Completed | Phase 2 | 2022-03-28 | Sheppard Pratt Health System, Baltimore |
| Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder | NCT05035927 | Completed | Phase 2 | 2022-03-16 | TRYP Therapeutics, Gainesville |
| Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care | NCT04950608 | Completed | Phase 2 | 2022-03-09 | Dana-Farber Cancer Institute, Danvers |
| Frontline Clinician Psilocybin Study | NCT05163496 | Completed | Phase 3 | 2022-03-03 | University of Washington, Seattle |
| Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought | NCT05301608 | Recruiting | Phase 1 | 2022-03-03 | Johns Hopkins University, Baltimore |
| Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department | NCT05217706 | Status not reported | Early Phase 1 | 2022-03-01 | Rady Children's Hospital, San Diego, San Diego |
| Intramuscular Ketamine for Suicidal Ideation | NCT05105061 | Withdrawn | Phase 2 | 2022-02-01 | Icahn School of Medicine at Mount Sinai, New York |
| Ketamine + Mindfulness for Depression | NCT05168735 | Completed | Phase 1 | 2022-02-01 | University of Pittsburgh, Pittsburgh |
| Psilocybin Therapy for Depression in Bipolar II Disorder | NCT05065294 | Active, not recruiting | Phase 2 | 2022-01-28 | University of California, San Francisco, San Francisco |
| Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine | NCT04613453 | Terminated | Phase 2 | 2022-01-21 | Yale University, New Haven |
| KAP for Depression in Abstinent Opioid Users | NCT05193318 | Terminated | Phase 2 | 2022-01-13 | Medical University of South Carolina, Charleston |
| Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy | NCT05274230 | Status not reported | Not applicable | 2021-12-08 | Apollo Neuroscience, Inc., Pittsburgh |
| Ketamine for the Treatment of Depression in Parkinson's Disease | NCT04944017 | Completed | Phase 2 | 2021-11-23 | Yale University, New Haven |
| Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure | NCT04313712 | Active, not recruiting | Not reported | 2021-11-15 | Stanford University, Stanford |
| Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG) | NCT05095792 | Terminated | Not reported | 2021-11-09 | Entheon Biomedical Corp., Austin |
| Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD | NCT04784143 | Terminated | Phase 2 | 2021-11-08 | Lykos Therapeutics, The Bronx |
| Stanford Regulating Circuits of the Brain Study - MDMA | NCT04060108 | Completed | Not reported | 2021-11-02 | Stanford University, Palo Alto |
| Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer | NCT04522804 | Completed | Early Phase 1 | 2021-10-04 | University of Utah, Salt Lake City |
| Repeated Neurocognitive Measurements in Depressed Patients | NCT04916548 | Completed | Phase 1 | 2021-09-16 | University of Pittsburgh, Pittsburgh |
| Visual Surround Suppression and Perceptual Expectation Under Psilocybin | NCT04424225 | Terminated | Phase 1 | 2021-08-30 | University of Minnesota, Minneapolis |
| Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease | NCT04932434 | Completed | Phase 2 | 2021-08-15 | University of California, San Francisco, San Francisco |
| Repeat Dosing of Psilocybin in Migraine Headache | NCT04218539 | Completed | Phase 1 | 2021-08-10 | Yale University, West Haven |
| Drug Effects on Interpersonal Interaction | NCT05123716 | Completed | Early Phase 1 | 2021-08-01 | University of Chicago, Chicago |
| MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD | NCT04264026 | Completed | Phase 2 | 2021-07-29 | VA Loma Linda Health Care System, Loma Linda |
| A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue | NCT04141696 | Completed | Phase 1 | 2021-07-26 | National Institutes of Health Clinical Center (CC), Bethesda |
| Understanding Ketamine's Dissociative Effects (KD Study) | NCT04861051 | Recruiting | Phase 1 | 2021-07-26 | Stanford University, Palo Alto |
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation | NCT04658420 | Status not reported | Phase 2 | 2021-07-01 | The University of Texas Health Science Center at Tyler, Tyler |
| Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD | NCT04889664 | Completed | Phase 2 | 2021-06-04 | Icahn School of Medicine at Mount Sinai, Manhattan |
| Precision Functional Brain Mapping in Psilocybin | NCT04501653 | Completed | Early Phase 1 | 2021-06-01 | Washington University School of Medicine, St Louis |
| Pilot RECAP Study in Healthy Volunteers | NCT04842045 | Completed | Phase 1 | 2021-05-21 | University of Wisconsin, Madison, Madison |
| Ketamine Assisted Psychotherapy for Opioid Use Disorder | NCT04892251 | Recruiting | Phase 1 | 2021-05-20 | University of Utah, Salt Lake City |
| Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | NCT04661514 | Completed | Phase 2 | 2021-05-01 | University of California, San Diego, La Jolla |
| Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder | NCT04620759 | Active, not recruiting | Phase 2 | 2021-04-14 | Johns Hopkins University, Baltimore |
| Modified Ketogenic Diet and Ketamine for Anorexia Nervosa | NCT04714541 | Completed | Phase 1 | 2021-04-12 | Homeostasis Therapeutics, LLC, South Windsor |
| Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | NCT04123314 | Recruiting | Early Phase 1 | 2021-03-24 | Johns Hopkins University, Baltimore |
| Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans | NCT04711915 | Active, not recruiting | Phase 1 | 2021-03-17 | Yale University, West Haven |
| Ketamine + Cognitive Training for Suicidality in the Medical Setting | NCT04578938 | Active, not recruiting | Phase 4 | 2021-03-15 | University of Pittsburgh, Pittsburgh |
| Ketamine-enhanced Prolonged Exposure Therapy in PTSD | NCT04560660 | Completed | Phase 2 | 2021-03-09 | VA Office of Research and Development, Minneapolis |
| A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD | NCT04714359 | Completed | Phase 3 | 2021-03-08 | Lykos Therapeutics, Los Angeles |
| Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention | NCT04760652 | Completed | Not applicable | 2021-03-05 | Yale University, Birmingham |
| The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | NCT04433845 | Status not reported | Phase 2 | 2021-03-01 | Sheppard Pratt Health System, Baltimore |
| An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) | NCT04433858 | Status not reported | Phase 2 | 2021-03-01 | Sheppard Pratt Health System, Palo Alto |
| Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD | NCT05066282 | Completed | Not reported | 2021-03-01 | Lykos Therapeutics, San Francisco |
| Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | NCT04656301 | Completed | Phase 2 | 2021-02-26 | New York State Psychiatric Institute, New York |
| Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder | NCT04410913 | Active, not recruiting | Phase 2 | 2021-02-18 | Saint John's Cancer Institute, Santa Monica |
| IM Ketamine vs Midazolam for Suicidal ER Patients | NCT04640636 | Suspended | Phase 4 | 2021-02-09 | New York State Psychiatric Institute, New York |
| Inpatient Single Dose Interventions for Alcohol Use Disorder | NCT04562779 | Completed | Early Phase 1 | 2021-01-19 | Denver Health and Hospital Authority, Denver |
| Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine | NCT04161066 | Recruiting | Phase 1 | 2021-01-13 | University of Wisconsin, Madison, Madison |
| Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine | NCT04711005 | Completed | Phase 1 | 2021-01-11 | National Institute of Mental Health (NIMH), Durham |
| Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1) | NCT04589208 | Active, not recruiting | Phase 1 | 2021-01-01 | New York State Psychiatric Institute, New York |
| Ketamine for the Treatment of Opioid Use Disorder and Depression | NCT04177706 | Completed | Phase 2 | 2020-12-17 | Medical University of South Carolina, Charleston |
| A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide | NCT04669665 | Completed | Phase 2 | 2020-12-17 | Seelos Therapeutics, Inc., Orange |
| Use of Transmucosal Ketamine in Post Stroke Depression | NCT04876066 | Status not reported | Phase 1 | 2020-11-30 | West Virginia University, Morgantown |
| A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression | NCT04599855 | Completed | Phase 4 | 2020-11-04 | Janssen Research & Development, LLC, Birmingham |
| University of Iowa Interventional Psychiatry Service Patient Registry | NCT04480918 | Recruiting | Not reported | 2020-11-02 | University of Iowa, Iowa City |
| The Effects of Low Dose Ketamine on Cardiovascular Function | NCT04429685 | Terminated | Phase 1 | 2020-11-01 | University of Texas Southwestern Medical Center, Dallas |
| Ketamine for Older Adults Pilot | NCT04504175 | Completed | Phase 4 | 2020-10-22 | Washington University School of Medicine, Los Angeles |
| Ketamine Treatment Effects on Synaptic Plasticity in Depression | NCT04091971 | Completed | Phase 4 | 2020-10-09 | New York State Psychiatric Institute, New York |
| A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) | NCT04077437 | Completed | Phase 3 | 2020-09-02 | Lykos Therapeutics, Los Angeles |
| The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder | NCT04593563 | Status not reported | Phase 2 | 2020-09-01 | Maryland Oncology Hematology, PA, Rockville |
| Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression | NCT04239963 | Completed | Not reported | 2020-08-17 | Mclean Hospital, Belmont |
| The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | NCT04739865 | Completed | Phase 2 | 2020-08-10 | COMPASS Pathways, La Jolla |
| Opiate Suicide Study in Patients With Major Depression | NCT04116528 | Active, not recruiting | Phase 3 | 2020-08-01 | Stanford University, Stanford |
| Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) | NCT04519957 | Completed | Not reported | 2020-07-20 | COMPASS Pathways, La Jolla |
| PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder | NCT04353921 | Terminated | Not reported | 2020-06-30 | Usona Institute, Lauderhill |
| Low Dose Ketamine Infusion for the Treatment of Resistant Depression | NCT04283058 | Withdrawn | Not reported | 2020-06-29 | Loma Linda University, Loma Linda |
| Intravenous Ketamine Effects on Functional Neuroanatomy | NCT04205890 | Withdrawn | Phase 1 | 2020-05-02 | Neurological Associates of West Los Angeles, Santa Monica |
| Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD) | NCT04352621 | Status not reported | Phase 4 | 2020-05-01 | University of Cincinnati, Cincinnati |
| A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health | NCT05604794 | Completed | Phase 4 | 2020-03-13 | Field Trip Health, Los Angeles |
| Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression | NCT03973268 | Recruiting | Phase 1 | 2020-01-21 | National Institutes of Health Clinical Center (CC), Bethesda |
| Intranasal Ketamine for Suicidal Ideation in Veterans | NCT03788694 | Withdrawn | Early Phase 1 | 2020-01-01 | Bronx Veterans Medical Research Foundation, Inc, The Bronx |
| The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women | NCT04285684 | Completed | Early Phase 1 | 2019-12-20 | The Ketamine Research Foundation, San Anselmo |
| Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot | NCT04154150 | Terminated | Phase 4 | 2019-12-19 | University of Pittsburgh, Pittsburgh |
| Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department | NCT04266288 | Completed | Phase 4 | 2019-10-18 | MercyOne Des Moines Medical Center, Des Moines |
| A Study of Psilocybin for Major Depressive Disorder (MDD) | NCT03866174 | Completed | Phase 2 | 2019-10-15 | Usona Institute, San Francisco |
| EEG Characteristics in ECT | NCT04022226 | Completed | Early Phase 1 | 2019-10-01 | University of New Mexico, Albuquerque |
| Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans | NCT04032301 | Completed | Phase 1 | 2019-09-30 | University of Minnesota, Minneapolis |
| THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis | NCT04199468 | Completed | Phase 1 | 2019-09-24 | Yale University, West Haven |
| A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study | NCT04103892 | Completed | Phase 2 | 2019-09-05 | Clexio Biosciences Ltd., Bentonville |
| Effects of Psilocybin in Anorexia Nervosa | NCT04052568 | Completed | Phase 1 | 2019-08-26 | Johns Hopkins University, Baltimore |
| Effects of Drugs on Responses to Brain and Emotional Processes | NCT04053036 | Completed | Early Phase 1 | 2019-08-08 | University of Chicago, Chicago |
| Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects | NCT04173962 | Completed | Phase 2 | 2019-08-08 | Icahn School of Medicine at Mount Sinai, New York |
| Endogenous Opioid Modulation by Ketamine | NCT03051945 | Withdrawn | Phase 3 | 2019-08-01 | University of Utah, Salt Lake City |
| Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease | NCT06021756 | Status not reported | Phase 1 | 2019-07-28 | University of Arizona, Tucson |
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy | NCT03889756 | Terminated | Phase 2 | 2019-07-17 | Yale University, New Haven |
| Ketamine for Mood Disorders With Suicidal Ideation | NCT04099771 | Status not reported | Early Phase 1 | 2019-07-01 | The Miriam Hospital, Providence |
| Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine | NCT04216888 | Completed | Phase 2 | 2019-06-26 | Nathan Kline Institute for Psychiatric Research, Orangeburg |
| NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression | NCT03396601 | Status not reported | Phase 3 | 2019-06-25 | NeuroRx, Inc., Hollywood |
| Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder | NCT05209217 | Status not reported | Not reported | 2019-06-04 | Mclean Hospital, Belmont |
| The Role of HNKs in the Antidepressant Effect of Ketamine | NCT03977675 | Terminated | Phase 1 | 2019-05-15 | Columbia University, New York |
| Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics | NCT03947099 | Completed | Not reported | 2019-05-02 | Klarisana Physician Services PLLC, San Antonio |
| Mood Effects of Serotonin Agonists Extended | NCT03934710 | Completed | Phase 1 | 2019-04-20 | University of Chicago, Chicago |
| Ketamine and Prolonged Exposure in PTSD | NCT03960658 | Completed | Phase 1 | 2019-04-03 | Minneapolis Veterans Affairs Medical Center, Minneapolis |
| Effects of Psilocybin in Concussion Headache | NCT03806985 | Terminated | Phase 1 | 2019-03-28 | Yale University, West Haven |
| Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression | NCT04011592 | Terminated | Phase 2 | 2019-03-04 | The University of Texas Health Science Center, Houston, Houston |
| The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | NCT03775200 | Completed | Phase 2 | 2019-03-01 | COMPASS Pathways, La Jolla |
| Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression | NCT03756129 | Completed | Phase 2 | 2019-02-08 | Novartis, Birmingham |
| Ketamine Associated ACC GABA and Glutamate Change and Depression Remission: | NCT03573349 | Active, not recruiting | Early Phase 1 | 2019-01-03 | Mayo Clinic, Rochester |
| Psilocybin for Treatment of Obsessive Compulsive Disorder | NCT03300947 | Completed | Phase 1 | 2019-01-02 | University of Arizona, Tucson |
| Ketamine for Major Depressive Disorder | NCT03721900 | Status not reported | Phase 1 | 2018-12-28 | Shenox Pharmaceuticals, LLC, Gaithersburg |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial | NCT03367533 | Completed | Phase 1 | 2018-11-29 | Yale University, New Haven |
| A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) | NCT03537014 | Completed | Phase 3 | 2018-11-21 | Lykos Therapeutics, North Hollywood |
| Epigenetics and MDMA-Assisted Psychotherapy for PTSD | NCT06189027 | Completed | Phase 3 | 2018-11-20 | University of Southern California, Los Angeles |
| Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. | NCT03356483 | Completed | Phase 1 | 2018-11-13 | Yale University, New Haven |
| Assessment of Abuse Potential of Rapastinel in Humans | NCT03799900 | Completed | Phase 1 | 2018-11-01 | Naurex, Inc, an affiliate of Allergan plc, Overland Park |
| Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine | NCT04856124 | Completed | Not reported | 2018-09-01 | Psych Atlanta, Marietta |
| Ketamine for Treatment of MS Fatigue | NCT03500289 | Completed | Phase 1 | 2018-08-10 | Johns Hopkins University, Baltimore |
| A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | NCT03434041 | Completed | Phase 3 | 2018-05-25 | Janssen Research & Development, LLC, Atlanta |
| Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse | NCT03539887 | Completed | Phase 3 | 2018-05-01 | The University of Texas Health Science Center, Houston, Houston |
| Mood Effects of Serotonin Agonists | NCT03790358 | Completed | Phase 1 | 2018-05-01 | University of Chicago, Chicago |
| Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder | NCT03554174 | Active, not recruiting | Phase 1 | 2018-02-27 | Yale University, West Haven |
| Ketamine in Borderline Personality Disorder | NCT03395314 | Terminated | Phase 2 | 2018-02-15 | Yale University, New Haven |
| Sequential Therapy for the Treatment of Severe Bipolar Depression. | NCT02974010 | Completed | Phase 2 | 2018-01-15 | NeuroRx, Inc., Birmingham |
| Ketamine Infusion for Comorbid PTSD and Chronic Pain | NCT04322968 | Completed | Phase 3 | 2018-01-09 | VA Ann Arbor Healthcare System, Ann Arbor |
| Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors | NCT02950467 | Completed | Phase 1 | 2018-01-05 | University of California, San Francisco, San Francisco |
| Intravenous Ketamine Plus Neurocognitive Training for Depression | NCT03237286 | Completed | Phase 1 | 2017-12-01 | University of Pittsburgh, Pittsburgh |
| Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine | NCT03290963 | Withdrawn | Phase 2 | 2017-11-30 | Mayo Clinic, Rochester |
| Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | NCT03282123 | Completed | Phase 2 | 2017-11-16 | Lykos Therapeutics, North Hollywood |
| Psilocybin for the Treatment of Migraine Headache | NCT03341689 | Completed | Phase 1 | 2017-11-01 | Yale University, West Haven |
| Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide | NCT03185819 | Completed | Phase 2 | 2017-10-05 | Janssen Research & Development, LLC, Hartford |
| A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD) | NCT03149991 | Completed | Phase 4 | 2017-09-14 | Massachusetts General Hospital, Garden Grove |
| Effects of Psilocybin in Major Depressive Disorder | NCT03181529 | Completed | Phase 2 | 2017-08-10 | Johns Hopkins University, Baltimore |
| Persisting Effects of Psilocybin | NCT02971605 | Completed | Phase 1 | 2017-07-01 | Johns Hopkins University, Baltimore |
| 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide | NCT03097133 | Completed | Phase 3 | 2017-06-15 | Janssen Research & Development, LLC, San Diego |
| 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide | NCT03039192 | Completed | Phase 3 | 2017-06-09 | Janssen Research & Development, LLC, Birmingham |
| The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. | NCT03156504 | Completed | Phase 4 | 2017-06-01 | Mayo Clinic, Baltimore |
| Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder | NCT03065335 | Recruiting | Phase 1 | 2017-05-25 | National Institutes of Health Clinical Center (CC), Bethesda |
| ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) | NCT03113968 | Completed | Phase 2 | 2017-04-07 | The Cleveland Clinic, New Haven |
| Evaluation of MDMA on Startle Response | NCT03181763 | Completed | Phase 1 | 2017-03-14 | Lykos Therapeutics, Atlanta |
| The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation. | NCT02997722 | Terminated | Phase 4 | 2017-03-02 | University of Mississippi Medical Center, Jackson |
| Ketamine and Nitroprusside for Depression | NCT03102736 | Completed | Phase 2 | 2017-02-14 | Icahn School of Medicine at Mount Sinai, New York |
| The Impact of Ketamine on the Reward Circuitry of Suicidal Patients | NCT02532153 | Withdrawn | Phase 3 | 2017-02-01 | Massachusetts General Hospital, Boston |
| Open Label Ketamine Treatment for Major Depressive Disorder in Veterans | NCT03053830 | Completed | Phase 2 | 2017-01-31 | VA Connecticut Healthcare System, West Haven |
| Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression | NCT03027362 | Completed | Not applicable | 2017-01-01 | Yale University, New Haven |
| Psilocybin for the Treatment of Cluster Headache | NCT02981173 | Completed | Phase 1 | 2016-12-05 | Yale University, West Haven |
| The UTHealth Ketamine Project | NCT02882711 | Terminated | Phase 2 | 2016-11-07 | The University of Texas Health Science Center, Houston, Houston |
| Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients | NCT02935595 | Completed | Phase 2 | 2016-10-14 | The University of Texas Health Science Center, Houston, Houston |
| Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD) | NCT02911597 | Completed | Phase 1 | 2016-09-01 | Stanford University, Stanford |
| Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers | NCT02442739 | Withdrawn | Early Phase 1 | 2016-08-15 | Cedars-Sinai Medical Center, Los Angeles |
| Emergency Ketamine Treatment of Suicidal Ideation | NCT02183272 | Status not reported | Phase 2 | 2016-08-01 | University of Cincinnati, Cincinnati |
| A Study to Decrease Suicidal Thinking Using Ketamine | NCT02418702 | Withdrawn | Phase 3 | 2016-08-01 | United States Naval Medical Center, San Diego, San Diego |
| MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD | NCT02876172 | Completed | Phase 1 | 2016-07-03 | Resilient Pharmaceuticals, Mt. Pleasant |
| Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects | NCT02669043 | Terminated | Not applicable | 2016-07-01 | Massachusetts General Hospital, Boston |
| A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression | NCT02782104 | Completed | Phase 3 | 2016-06-09 | Janssen Research & Development, LLC, Birmingham |
| Understanding How Ketamine Brings About Rapid Improvement in OCD | NCT02624596 | Completed | Phase 2 | 2016-06-01 | Stanford University, Stanford |
| Effect of Stimulant Drugs on Social Perception | NCT03790618 | Completed | Phase 1 | 2016-06-01 | University of Chicago, Chicago |
| CAP-Ketamine for Antidepressant Resistant PTSD | NCT02655692 | Completed | Phase 2 | 2016-04-18 | VA Office of Research and Development, West Haven |
| Imaging SV2A in Mood Disorders | NCT02734602 | Active, not recruiting | Not applicable | 2016-04-01 | Yale University, New Haven |
| Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia | NCT02761330 | Completed | Not applicable | 2016-04-01 | Washington University School of Medicine, St Louis |
| Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects | NCT02487485 | Completed | Phase 2 | 2016-03-01 | Yale University, New Haven |
| Ketamine for Depression: An MRI Study | NCT02544607 | Completed | Phase 4 | 2016-03-01 | Massachusetts General Hospital, Boston |
| Ketamine Anesthesia for Improvement of Depression in ECT | NCT02752724 | Completed | Not applicable | 2016-03-01 | VA Puget Sound Health Care System, Seattle |
| Neurobiology of Suicide | NCT02543983 | Recruiting | Phase 2 | 2015-12-01 | National Institutes of Health Clinical Center (CC), Bethesda |
| Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy | NCT02727998 | Terminated | Phase 2 | 2015-12-01 | Yale University, New Haven |
| A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | NCT02493868 | Completed | Phase 3 | 2015-10-01 | Janssen Research & Development, LLC, Birmingham |
| Ketamine for Treatment Resistant Late-Life Depression | NCT02556606 | Completed | Phase 3 | 2015-10-01 | VA Office of Research and Development, Houston |
| Ketamine Infusion for Adolescent Depression and Anxiety | NCT02579928 | Completed | Phase 4 | 2015-10-01 | Yale University, New Haven |
| A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | NCT02497287 | Completed | Phase 3 | 2015-09-30 | Janssen Research & Development, LLC, New Haven |
| Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder | NCT01613820 | Withdrawn | Not applicable | 2015-09-01 | Massachusetts General Hospital, Boston |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression | NCT02422186 | Completed | Phase 3 | 2015-08-20 | Janssen Research & Development, LLC, San Diego |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | NCT02417064 | Completed | Phase 3 | 2015-08-10 | Janssen Research & Development, LLC, Birmingham |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | NCT02418585 | Completed | Phase 3 | 2015-08-07 | Janssen Research & Development, LLC, Birmingham |
| Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression | NCT02522377 | Completed | Not applicable | 2015-08-01 | The Cleveland Clinic, Cleveland |
| Intranasal Ketamine for Late-Life Depression and Suicidal Ideation | NCT02295787 | Withdrawn | Phase 4 | 2015-07-01 | Massachusetts General Hospital, Palo Alto |
| Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial | NCT01892995 | Status not reported | Not applicable | 2015-06-01 | Brooke Army Medical Center, Fort Sam Houston |
| Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD) | NCT02397889 | Completed | Phase 2 | 2015-05-18 | Icahn School of Medicine at Mount Sinai, New York |
| MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness | NCT02427568 | Completed | Phase 2 | 2015-05-14 | Lykos Therapeutics, San Anselmo |
| Psilocybin-facilitated Treatment for Cocaine Use | NCT02037126 | Completed | Phase 2 | 2015-05-01 | University of Alabama at Birmingham, Birmingham |
| Ketamine Infusions for PTSD and Treatment-Resistant Depression | NCT02577250 | Completed | Phase 1 | 2015-05-01 | Minneapolis Veterans Affairs Medical Center, Minneapolis |
| miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome | NCT02418195 | Completed | Phase 2 | 2015-04-20 | University of Alabama at Birmingham, Birmingham |
| Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression | NCT02360280 | Completed | Phase 2 | 2015-04-01 | VA Office of Research and Development, Minneapolis |
| The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals | NCT02421263 | Completed | Phase 1 | 2015-04-01 | NYU Langone Health, New York |
| Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion | NCT02243813 | Completed | Phase 1 | 2015-03-01 | Johns Hopkins University, Baltimore |
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD) | NCT02422290 | Completed | Phase 1 | 2015-03-01 | New York State Psychiatric Institute, New York |
| Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine | NCT02289248 | Completed | Phase 1 | 2015-02-01 | Yale University, New Haven |
| Ketamine Infusion for Social Anxiety Disorder | NCT02083926 | Completed | Early Phase 1 | 2015-01-02 | Yale University, New Haven |
| Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder | NCT02461927 | Completed | Phase 1 | 2015-01-01 | VA Office of Research and Development, West Haven |
| Effect of Ketamine on Fatigue Following Cancer Therapy | NCT02317341 | Terminated | Early Phase 1 | 2014-12-13 | National Institutes of Health Clinical Center (CC), Bethesda |
| Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | NCT01920555 | Completed | Phase 2 | 2014-12-01 | Massachusetts General Hospital, Palo Alto |
| To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD | NCT02398136 | Withdrawn | Phase 2 | 2014-12-01 | Icahn School of Medicine at Mount Sinai, New York |
| Effects of MDMA on Emotional and Social Memories | NCT03050541 | Completed | Not applicable | 2014-12-01 | University of Chicago, Chicago |
| Evaluating Ketamine and Psychological Sequelae | NCT04053400 | Completed | Not reported | 2014-12-01 | Defense and Veterans Center for Integrative Pain Management, Bethesda |
| Ketamine in Adolescents With Treatment-Resistant Depression | NCT02078817 | Completed | Phase 2 | 2014-09-01 | University of Minnesota, Minneapolis |
| Ketamine for Depression and Suicide Risk | NCT02094898 | Completed | Phase 2 | 2014-09-01 | Mayo Clinic, Rochester |
| Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD | NCT02206776 | Terminated | Phase 2 | 2014-09-01 | New York State Psychiatric Institute, New York |
| A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder | NCT02234011 | Terminated | Phase 2 | 2014-09-01 | Mclean Hospital, Belmont |
| A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence | NCT02061293 | Completed | Phase 2 | 2014-06-01 | NYU Langone Health, Albuquerque |
| UW Psilocybin Pharmacokinetics Study | NCT02163707 | Completed | Phase 1 | 2014-06-01 | University of Wisconsin, Madison, Madison |
| Biomarkers of Fast Acting Therapies in Major Depression | NCT02165449 | Completed | Phase 1 | 2014-06-01 | University of California, Los Angeles, Los Angeles |
| A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide | NCT02133001 | Completed | Phase 2 | 2014-05-23 | Janssen Research & Development, LLC, Birmingham |
| Biomarker Assessment of Glutamatergic Target Engagement | NCT02134951 | Completed | Phase 4 | 2014-05-01 | New York State Psychiatric Institute, Sacramento |
| Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators | NCT02145091 | Completed | Phase 1 | 2014-05-01 | Johns Hopkins University, Baltimore |
| Ketamine Alcohol (in Treatment-Resistant Depression) | NCT02122562 | Recruiting | Phase 2 | 2014-04-23 | University of Iowa, Iowa City |
| Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults | NCT02008396 | Completed | Phase 2 | 2014-04-11 | Lykos Therapeutics, Torrance |
| A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder | NCT01957410 | Terminated | Phase 2 | 2014-02-01 | Janssen Research & Development, LLC, Durham |
| A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression | NCT01998958 | Completed | Phase 2 | 2014-01-27 | Janssen Research & Development, LLC, Birmingham |
| Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD | NCT02102802 | Completed | Not reported | 2014-01-01 | Lykos Therapeutics, Mt. Pleasant |
| Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP) | NCT02062658 | Completed | Phase 2 | 2013-12-01 | New York State Psychiatric Institute, New York |
| Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients | NCT02106325 | Completed | Phase 2 | 2013-12-01 | NYU Langone Health, New York |
| Ketamine for Suicidality in Bipolar Depression | NCT01944293 | Completed | Phase 1 | 2013-09-01 | New York State Psychiatric Institute, New York |
| Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults | NCT01892189 | Completed | Phase 1 | 2013-08-01 | Takeda, Salt Lake City |
| TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD | NCT02766192 | Status not reported | Not applicable | 2013-08-01 | The Cooper Health System, Camden |
| Ketamine Plus Lithium in Treatment-Resistant Depression | NCT01880593 | Completed | Phase 2 | 2013-07-01 | Icahn School of Medicine at Mount Sinai, New York |
| An Open Prospective Trial of IV Ketamine in Suicidal Adolescents | NCT02048423 | Status not reported | Phase 2 | 2013-06-01 | Nationwide Children's Hospital, Columbus |
| Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | NCT01793610 | Completed | Phase 2 | 2013-05-13 | Lykos Therapeutics, Boulder |
| Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators | NCT01988311 | Completed | Phase 1 | 2013-05-01 | Johns Hopkins University, Baltimore |
| Characterizing Clinical and Pharmacological Neuroimaging Biomarkers | NCT03842800 | Completed | Early Phase 1 | 2013-04-01 | Yale University, New Haven |
| NMDA Antagonists in Bipolar Depression | NCT01833897 | Completed | Phase 4 | 2013-03-01 | New York State Psychiatric Institute, New York |
| Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder | NCT01667926 | Completed | Not applicable | 2013-01-01 | Massachusetts General Hospital, Boston |
| Trial of Ketamine and Lithium Therapy in Bipolar Depression | NCT01768767 | Withdrawn | Phase 2 | 2013-01-01 | Yale University, West Haven |
| A Study of Ketamine in Patients With Treatment-resistant Depression | NCT01627782 | Completed | Phase 2 | 2012-08-06 | Janssen Research & Development, LLC, Birmingham |
| Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer | NCT01680172 | Terminated | Phase 2 | 2012-08-01 | Mayo Clinic, Scottsdale |
| Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder | NCT01504659 | Terminated | Phase 2 | 2012-07-01 | Juvenile Bipolar Research Foundation, Not Predetermined |
| Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder | NCT01371110 | Terminated | Phase 1 | 2012-06-01 | Baylor College of Medicine, New York |
| PET Imaging of mGLuR5 With Drug Challenge | NCT01691092 | Completed | Not applicable | 2012-06-01 | Yale University, New Haven |
| Ketamine in the Treatment of Suicidal Depression | NCT01700829 | Completed | Phase 4 | 2012-06-01 | New York State Psychiatric Institute, New York |
| Treatment of Suicidal Ideation With Intravenous Ketamine Infusion | NCT01887990 | Completed | Not applicable | 2012-05-01 | University of Alabama at Birmingham, Birmingham |
| Treatment Resistant Depression (Pilot) | NCT01179009 | Completed | Not applicable | 2012-04-01 | Washington University School of Medicine, St Louis |
| Ketamine Infusion for Treatment-resistant Major Depressive Disorder | NCT01582945 | Completed | Not applicable | 2012-04-01 | Massachusetts General Hospital, Boston |
| Ketamine for Depression and Alcohol Dependence | NCT01551329 | Completed | Phase 1 | 2012-03-01 | Yale University, West Haven |
| The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence | NCT01535937 | Terminated | Phase 1 | 2012-02-01 | New York State Psychiatric Institute, New York |
| Ketamine in the Treatment of Depression | NCT01558063 | Completed | Phase 2 | 2012-02-01 | Columbia University, New York |
| Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | NCT00979693 | Withdrawn | Phase 2 | 2012-01-01 | Multidisciplinary Association for Psychedelic Studies, Miami Beach |
| Ketamine For Suicidal Ideation | NCT01507181 | Completed | Phase 4 | 2012-01-01 | Icahn School of Medicine at Mount Sinai, New York |
| Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence | NCT01534494 | Completed | Phase 2 | 2012-01-01 | University of New Mexico, Albuquerque |
| Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression | NCT02378415 | Terminated | Phase 1 | 2011-12-01 | United States Naval Medical Center, San Diego, San Diego |
| Intranasal Ketamine in Treatment-Resistant Depression | NCT01304147 | Completed | Not applicable | 2011-10-01 | Icahn School of Medicine at Mount Sinai, New York |
| Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time | NCT01567852 | Completed | Not applicable | 2011-08-01 | University of New Mexico, Albuquerque |
| Ketamine Anesthesia in Electroconvulsive Therapy | NCT01367119 | Completed | Not applicable | 2011-05-01 | Mayo Clinic, Rochester |
| Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers | NCT01404754 | Completed | Phase 1 | 2011-04-09 | Lykos Therapeutics, Boulder |
| Glutamatergic Modulation of Cocaine-related Deficits | NCT01790490 | Completed | Phase 2 | 2011-02-01 | New York State Psychiatric Institute, New York |
| Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial | NCT01458327 | Completed | Phase 2 | 2010-12-15 | Lykos Therapeutics, Mt. Pleasant |
| Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder | NCT01211405 | Completed | Phase 2 | 2010-11-10 | Lykos Therapeutics, Mt. Pleasant |
| N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression | NCT01260649 | Terminated | Phase 4 | 2010-11-01 | Massachusetts General Hospital, Boston |
| Effects of MDMA on Social and Emotional Processing | NCT01849419 | Completed | Not applicable | 2010-07-01 | University of Chicago, Chicago |
| Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression | NCT01881763 | Completed | Phase 4 | 2010-06-01 | Northwell Health, Glen Oaks |
| Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition. | NCT01053403 | Completed | Not applicable | 2010-04-01 | California Pacific Medical Center Research Institute, San Francisco |
| Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD) | NCT01100255 | Completed | Phase 2 | 2010-04-01 | New York State Psychiatric Institute, New York |
| Ketamine for Low Mood States in the ER | NCT01209845 | Completed | Phase 1 | 2010-04-01 | Yale University, New Haven |
| Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression | NCT01309581 | Terminated | Not applicable | 2010-04-01 | Icahn School of Medicine at Mount Sinai, New York |
| Psilocybin and Spiritual Practice | NCT00802282 | Completed | Phase 1 | 2009-08-01 | Johns Hopkins University, Baltimore |
| Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder | NCT00956085 | Completed | Phase 2 | 2009-08-01 | New York State Psychiatric Institute, New York |
| Treatment Study of Bipolar Depression | NCT00947791 | Terminated | Phase 4 | 2009-07-01 | Icahn School of Medicine at Mount Sinai, New York |
| Role of Serotonin in Acute and Subacute MDMA Effects | NCT00838305 | Completed | Not applicable | 2009-02-01 | California Pacific Medical Center Research Institute, San Francisco |
| Psilocybin Cancer Anxiety Study | NCT00957359 | Completed | Early Phase 1 | 2009-02-01 | NYU Langone Health, New York |
| Ketamine Infusion for Obsessive-Compulsive Disorder | NCT01349231 | Completed | Phase 2 | 2009-02-01 | Yale University, New Haven |
| Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD) | NCT00749203 | Completed | Phase 2 | 2009-01-01 | Icahn School of Medicine at Mount Sinai, New York |
| Optimization of IV Ketamine for Treatment Resistant Depression | NCT00768430 | Completed | Phase 2 | 2008-11-01 | Baylor College of Medicine, New York |
| Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study | NCT01943994 | Completed | Not applicable | 2008-09-01 | Johns Hopkins University, Baltimore |
| Ketamine Frequency Treatment for Major Depressive Disorder | NCT00646087 | Withdrawn | Phase 4 | 2008-03-01 | Essentia Health, Duluth |
| Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects | NCT00700076 | Completed | Phase 1 | 2008-01-22 | Yale University, West Haven |
| Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism | NCT02675530 | Completed | Phase 1 | 2007-12-01 | Yale University, West Haven |
| Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients | NCT00471445 | Completed | Phase 3 | 2007-10-01 | University of Rochester, Honolulu |
| Continuation Ketamine in Major Depression | NCT00548964 | Completed | Phase 1 | 2007-10-01 | Icahn School of Medicine at Mount Sinai, New York |
| Psychopharmacology of Psilocybin in Cancer Patients | NCT00465595 | Completed | Phase 2 | 2007-04-01 | Johns Hopkins University, Baltimore |
| MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer | NCT00252174 | Terminated | Phase 2 | 2007-02-01 | Brigham and Women's Hospital, Belmont |
| Research Study for Major Depressive Disorder: Investigation of Glutamate Medications | NCT00419003 | Completed | Phase 4 | 2006-12-01 | Baylor College of Medicine, New York |
| Rapid Antidepressant Effects of Ketamine in Major Depression | NCT00088699 | Completed | Phase 1 | 2004-07-26 | National Institutes of Health Clinical Center (CC), Bethesda |
| Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety | NCT00302744 | Completed | Phase 1 | 2004-04-01 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance |
| MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder | NCT00090064 | Completed | Phase 2 | 2004-03-12 | Lykos Therapeutics, Mt. Pleasant |
| Neurobiology and Pharmacokinets of Acute MDMA Administration | NCT01148342 | Completed | Phase 1 | 2004-02-10 | National Institutes of Health Clinical Center (CC), Baltimore |
| Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects | NCT00690170 | Completed | Phase 1 | 2002-12-01 | Yale University, West Haven |
| A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD | NCT04438512 | Status not reported | Not reported | Not reported | Lykos Therapeutics, Rockville |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ketamine | Ibogaine
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- Johns Hopkins University: 33 studies
- Yale University (New Haven): 31 studies
- Icahn School of Medicine at Mount Sinai: 19 studies
- New York State Psychiatric Institute: 16 studies
- Yale University (West Haven): 16 studies
- University of California, San Francisco: 14 studies
- University of Chicago: 12 studies
- Massachusetts General Hospital (Boston): 10 studies
- University of Wisconsin, Madison: 10 studies
- Janssen Research & Development, LLC: 9 studies
- Washington University School of Medicine: 9 studies
- National Institutes of Health Clinical Center (CC): 8 studies
- University of New Mexico: 8 studies
- University of Pittsburgh: 8 studies
- University of California, Los Angeles: 7 studies
- University of Washington: 7 studies
- Emory University: 6 studies
- NYU Langone Health: 6 studies
- Stanford University (Stanford): 6 studies
- University of Alabama at Birmingham: 6 studies
- Lykos Therapeutics (Torrance): 5 studies
- Mayo Clinic: 5 studies
- The University of Texas Health Science Center, Houston: 5 studies
- University of Utah: 5 studies
- COMPASS Pathways: 4 studies
- Lykos Therapeutics (Mt. Pleasant): 4 studies
- Mclean Hospital: 4 studies
- Stanford University (Palo Alto): 4 studies
- Sunstone Medical: 4 studies
- University of Iowa: 4 studies
- University of Minnesota: 4 studies
- Baylor College of Medicine: 3 studies
- Brigham and Women's Hospital: 3 studies
- M.D. Anderson Cancer Center: 3 studies
- Massachusetts General Hospital (Palo Alto): 3 studies
- Minneapolis Veterans Affairs Medical Center: 3 studies
- Ohio State University: 3 studies
- University of Arizona: 3 studies
- University of California, San Diego (San Diego): 3 studies
- University of California, San Diego (La Jolla): 3 studies
- University of Pennsylvania: 3 studies
- University of Texas at Austin: 3 studies
- University of Texas Southwestern Medical Center: 3 studies
- VA Office of Research and Development: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
Other country hubs
Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland